Database Query Results : , , TumCI

TumCI, Tumor Cell invasion: Click to Expand ⟱
Source:
Type:
Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms:

1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion.

2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue.

3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment.

4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream.

5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body.

6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection.

7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs.

8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis.
Scientific Papers found: Click to Expand⟱
297- ALA,    Insights on the Use of α-Lipoic Acid for Therapeutic Purposes
- Review, BC, SkBr3 - Review, neuroblastoma, SK-N-SH - Review, AD, NA
PDH↑, TumCG↓, ROS↑, AMPK↑, EGR4↓, Half-Life↓, BioAv↝, *GSH↑, *IronCh↑, *ROS↓, *antiOx↑, *neuroP↑, *Ach↑, *lipid-P↓, *IL1β↓, *IL6↓, TumCP↓, FDG↓, Apoptosis↑, AMPK↑, mTOR↓, EGFR↓, TumCI↓, TumCMig↓, *memory↑, *BioAv↑, *BioAv↝, *other↓, *other↝, *Half-Life↓, *BioAv↑, *ChAT↑, *GlucoseCon↑,
1124- ALA,    Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells
- in-vitro, Thyroid, BCPAP - in-vitro, Thyroid, HTH-83 - in-vitro, Thyroid, CAL-62 - in-vitro, Thyroid, FTC-133 - in-vivo, NA, NA
TumCP↓, AMPK↑, mTOR↓, TumCMig↓, TumCI↓, EMT↓, E-cadherin↑, β-catenin/ZEB1↓, Vim↓, Snail↓, Twist↓, TGF-β↓, p‑SMAD2↓, TumCG↓,
3442- ALA,    α‑lipoic acid modulates prostate cancer cell growth and bone cell differentiation
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, C4-2B - in-vitro, Nor, 3T3
tumCV↓, TumCMig↓, TumCI↓, ROS↑, Hif1a↑, JNK↑, Casp↑, TumCCA↑, Apoptosis↑, selectivity↑,
1252- aLinA,    α-Linolenic acid induces apoptosis, inhibits the invasion and metastasis, and arrests cell cycle in human breast cancer cells by inhibiting fatty acid synthase
- in-vitro, BC, NA
FASN↓, Apoptosis↑, TumCI↓, TumMeta↓, TumCCA↑,
1123- aLinA,    Linoleic acid induces an EMT-like process in mammary epithelial cells MCF10A
- in-vitro, BC, NA - in-vitro, NA, MCF10
TumCP↑, E-cadherin↓, Snail↑, Twist↑, ZEB2↑, FAK↑, NF-kB↑, MMP2↓, MMP9↓, *EMT↑, TumCI↑,
1157- And,    Andrographolide suppresses the migratory ability of human glioblastoma multiforme cells by targeting ERK1/2-mediated matrix metalloproteinase-2 expression
- in-vitro, GBM, GBM8401 - in-vitro, GBM, U251
TumCI↓, TumCMig↓, MMP2↓, ERK↝,
1545- Api,    The Potential Role of Apigenin in Cancer Prevention and Treatment
- Review, NA, NA
TNF-α↓, IL6↓, IL1α↓, P53↑, Bcl-xL↓, Bcl-2↓, BAX↑, Hif1a↓, VEGF↓, TumCCA↑, DNAdam↑, Apoptosis↑, CycB/CCNB1↓, cycA1/CCNA1↓, CDK1↓, PI3K↓, Akt↓, mTOR↓, IKKα↓, ERK↓, p‑Akt↓, p‑P70S6K↓, p‑S6↓, p‑ERK↓, p‑P90RSK↑, STAT3↓, MMP2↓, MMP9↓, TumCP↓, TumCMig↓, TumCI↓, Wnt/(β-catenin)↓,
1548- Api,    A comprehensive view on the apigenin impact on colorectal cancer: Focusing on cellular and molecular mechanisms
- Review, Colon, NA
*BioAv↓, *Half-Life∅, selectivity↑, *toxicity↓, Wnt/(β-catenin)↓, P53↑, P21↑, PI3K↓, Akt↓, mTOR↓, TumCCA↑, TumCI↓, TumCMig↓, STAT3↓, PKM2↓, EMT↓, cl‑PARP↑, Casp3↑, Bax:Bcl2↑, VEGF↓, Hif1a↓, Dose∅, GLUT1↓, GlucoseCon↓,
1565- Api,    Apigenin-7-glucoside induces apoptosis and ROS accumulation in lung cancer cells, and inhibits PI3K/Akt/mTOR pathway
- in-vitro, Lung, A549 - in-vitro, Nor, BEAS-2B - in-vitro, Lung, H1975
TumCP↓, Apoptosis↑, TumCMig↓, TumCI↓, Cyt‑c↑, MDA↑, GSH↓, ROS↑, PI3K↓, Akt↓, mTOR↓,
2593- Api,    Apigenin promotes apoptosis of 4T1 cells through PI3K/AKT/Nrf2 pathway and improves tumor immune microenvironment in vivo
- in-vivo, BC, 4T1
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, MMP↑, ROS↑, p‑PI3K↓, PI3K↓, Akt↓, NRF2↓, AntiTum↑, OS↑,
2632- Api,    Apigenin inhibits migration and induces apoptosis of human endometrial carcinoma Ishikawa cells via PI3K-AKT-GSK-3β pathway and endoplasmic reticulum stress
- in-vitro, EC, NA
TumCP↓, TumCCA↑, Apoptosis↑, Bcl-2↓, BAX↑, Bak↑, Casp↑, ER Stress↑, Ca+2↑, ATF4↑, CHOP↑, ROS↑, MMP↓, TumCMig↓, TumCI↓, eff↑, P53↑, P21↑, Cyt‑c↑, Casp9↑, Casp3↑, Bcl-xL↓,
2641- Api,    Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells
- in-vitro, BC, MDA-MB-231
TumCMig↓, TumCI↓, ITGB4↓,
2640- Api,    Apigenin: A Promising Molecule for Cancer Prevention
- Review, Var, NA
chemoPv↑, ITGB4↓, TumCI↓, TumMeta↓, Akt↓, ERK↓, p‑JNK↓, *Inflam↓, *PKCδ↓, *MAPK↓, EGFR↓, CK2↓, TumCCA↑, CDK1↓, P53↓, P21↑, Bax:Bcl2↑, Cyt‑c↑, APAF1↑, Casp↑, cl‑PARP↑, VEGF↓, Hif1a↓, IGF-1↓, IGFBP3↑, E-cadherin↑, β-catenin/ZEB1↓, HSPs↓, Telomerase↓, FASN↓, MMPs↓, HER2/EBBR2↓, CK2↓, eff↑, AntiAg↑, eff↑, FAK↓, ROS↑, Bcl-2↓, Cyt‑c↑, cl‑Casp3↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑, cl‑IAP2↑, AR↓, PSA↓, p‑pRB↓, p‑GSK‐3β↓, CDK4↓, ChemoSen↑, Ca+2↑, cal2↑,
3396- ART/DHA,    Progress on the study of the anticancer effects of artesunate
- Review, Var, NA
TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, Diff↑, TumAuto↑, angioG↓, TumCCA↑, ROS↑, AMPK↑, mTOR↑, ChemoSen↑, Tf↑, Ferroptosis↑, Ferritin↓, lipid-P↑, CDK1↑, CDK2↑, CDK4↑, CDK6↑, SIRT1↑, COX2↓, IL1β↓, survivin↓, DNAdam↑, RadioS↑,
1099- ART/DHA,    Dihydroartemisinin inhibits IL-6-induced epithelial–mesenchymal transition in laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/β-catenin signaling pathway
- in-vitro, NA, NA
EMT↓, TumCI↓, STAT3↓, β-catenin/ZEB1↓,
574- ART/DHA,    Dihydroartemisinin suppresses glioma proliferation and invasion via inhibition of the ADAM17 pathway
TumCP↓, TumCMig↓, TumCI↓, MMP17↓, p‑EGFR↓, p‑Akt↓,
570- ART/DHA,    Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling
- vitro+vivo, NSCLC, A549 - vitro+vivo, NSCLC, H1299
TumCCA↑, CSCs↓, TumCI↓, TumCMig↓, TumCG↓, Wnt/(β-catenin)↓, Nanog↓, SOX2↓, OCT4↓, N-cadherin↓, Vim↓, E-cadherin↑,
1338- AS,    The Modulatory Properties of Astragalus membranaceus Treatment on Triple-Negative Breast Cancer: An Integrated Pharmacological Method
- in-vitro, BC, NA
TumCI↓, Apoptosis↑, Symptoms↓, PIK3CA↓, Akt↓, Bcl-2↓,
1333- AS,    Astragalus polysaccharide inhibits breast cancer cell migration and invasion by regulating epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway
- in-vitro, BC, NA
TumCMig↓, TumCI↓, Ki-67↓, TumCP↓, Snail↓, Vim↓, E-cadherin↑, Wnt↓, β-catenin/ZEB1↓,
1358- Ash,    Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms
- Review, Var, NA
TumCCA↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, TumCP↓, CSCs↓, TumMeta↓, EMT↓, angioG↓, Vim↓, HSP90↓, annexin II↓, m-FAM72A↓, BCR-ABL↓, Mortalin↓, NRF2↓, cMYB↓, ROS↑, ChemoSen↑, eff↑, ChemoSen↑, ChemoSen↑, eff↑, *BioAv↓, ROCK1↓, TumCI↓, Sp1/3/4↓, VEGF↓, Hif1a↓, EGFR↓,
1181- Ash,    Withaferin A inhibits Epithelial to Mesenchymal Transition in Non-Small Cell Lung Cancer Cells
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
TumCMig↓, TumCI↓, EMT↓, p‑SMAD2↓, p‑SMAD3↓, p‑NF-kB↓,
1173- Ash,    Withaferin A inhibits proliferation of human endometrial cancer cells via transforming growth factor-β (TGF-β) signalling
- in-vitro, EC, K1 - in-vitro, Nor, THESCs
TumCP↓, *toxicity↓, Apoptosis↑, TumCCA↑, TumCMig↓, TumCI↓, p‑SMAD2↓, TGF-β↓, *toxicity↓,
3174- Ash,    Withaferin A Acts as a Novel Regulator of Liver X Receptor-α in HCC
- in-vitro, HCC, HepG2 - in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7
NF-kB↓, angioG↓, Inflam↓, TumCP↓, TumCMig↓, TumCI↓, Sp1/3/4↓, VEGF↓, angioG↓, uPA↓, PDGF↓, MCP1↓, ICAM-1↓, *NRF2↑, *hepatoP↑,
3172- Ash,    Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis
- in-vitro, HCC, HepG2 - in-vitro, Nor, HL7702
Keap1↑, NRF2↓, EMT↓, TumCP↓, TumCI↓, selectivity↑, *toxicity↓, ROS↑, MDA↑, GSH↓, Ferroptosis↑,
4808- ASTX,    Anti-Tumor Effects of Astaxanthin by Inhibition of the Expression of STAT3 in Prostate Cancer
- in-vitro, Pca, DU145 - in-vivo, NA, NA
TumCP↓, STAT3↓, Apoptosis↑, TumCMig↓, TumCI↓,
4820- ASTX,    Astaxanthin suppresses the malignant behaviors of nasopharyngeal carcinoma cells by blocking PI3K/AKT and NF-κB pathways via miR-29a-3p
- in-vitro, NPC, NA
TumCP↓, TumCI↓, Apoptosis↑, TumCCA↑, cycD1/CCND1↓, Bcl-2↓, P21↑, BAX↑, PI3K↓, Akt↓, NF-kB↓, miR-29b↑,
2047- BA,    Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells
- in-vitro, CRC, T24 - in-vitro, Nor, SV-HUC-1 - in-vitro, Bladder, 5637 - in-vivo, NA, NA
HDAC↓, AntiTum↑, TumCMig↓, AMPK↑, mTOR↑, TumAuto↑, ROS↑, miR-139-5p↑, BMI1↓, TumCI?, E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, cl‑PARP↑, cl‑Casp3↑, BAX↑, Bcl-2↓, Bcl-xL↓, MMP↓, PINK1↑, PARK2↑, TumMeta↓, TumCG↓, LC3II↑, p62↓, eff↓,
2606- Ba,    Baicalein: A review of its anti-cancer effects and mechanisms in Hepatocellular Carcinoma
- Review, HCC, NA
ChemoSen↑, TumCP↓, TumCCA↑, TumCMig↓, TumCI↓, MMPs↓, MAPK↓, TGF-β↓, ZFX↓, p‑MEK↓, ERK↓, MMP2↓, MMP9↓, uPA↓, TIMP1↓, TIMP2↓, NF-kB↓, p65↓, p‑IKKα↓, Fas↑, Casp2↑, Casp3↑, Casp8↑, Casp9↑, Bcl-xL↓, BAX↑, ER Stress↑, Ca+2↑, JNK↑, P53↑, ROS↑, H2O2↑, cMyc↓, CD24↓, 12LOX↓,
2296- Ba,    The most recent progress of baicalein in its anti-neoplastic effects and mechanisms
- Review, Var, NA
CDK1↓, Cyc↓, p27↑, P21↑, P53↑, TumCCA↑, TumCI↓, MMP2↓, MMP9↓, E-cadherin↑, N-cadherin↓, Vim↓, LC3A↑, p62↓, p‑mTOR↓, PD-L1↓, CAFs/TAFs↓, VEGF↓, ROCK1↓, Bcl-2↓, Bcl-xL↓, BAX↑, ROS↑, cl‑PARP↑, Casp3↑, Casp9↑, PTEN↑, MMP↓, Cyt‑c↑, Ca+2↑, PERK↑, IRE1↑, CHOP↑, Copper↑, Snail↓, Vim↓, Twist↓, GSH↓, NRF2↓, HO-1↓, GPx4↓, XIAP↓, survivin↓, DR5↑,
2700- BBR,    Cell-specific pattern of berberine pleiotropic effects on different human cell lines
- in-vitro, GBM, U343 - in-vitro, GBM, MIA PaCa-2 - in-vitro, Nor, HDFa
selectivity↑, TumCCA↑, Casp3↑, TumCI↓, TumCMig↓, N-cadherin?, DNMT1↑,
2702- BBR,    The enhancement of combination of berberine and metformin in inhibition of DNMT1 gene expression through interplay of SP1 and PDPK1
- in-vitro, Lung, A549 - in-vitro, Lung, H1975
TumCG↓, MAPK↓, FOXO3↑, TumCCA↑, TumCMig↓, TumCI↓, Sp1/3/4↓, PDK1↓, DNMT1↓, eff↑,
2709- BBR,    Berberine inhibits the glycolysis and proliferation of hepatocellular carcinoma cells by down-regulating HIF-1α
- in-vitro, HCC, HepG2
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, Glycolysis↓, Hif1a↓, GLUT1↓, HK2↓, PKM2↓, LDHA↓,
2711- BBR,    Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, FGF↓, IGFBP3↑,
2694- BBR,    Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells
- in-vitro, BC, NA
IL8↓, TumCI↓, EGFR↓, MEK↓, ERK↓, TGF-β1↓, VEGF↓,
2674- BBR,    Berberine: A novel therapeutic strategy for cancer
- Review, Var, NA - Review, IBD, NA
Inflam↓, AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumMeta↓, TumCI↓, eff↑, eff↑, CD4+↓, TNF-α↓, IL1↓, BioAv↓, BioAv↓, other↓, AMPK↑, MAPK↓, NF-kB↓, IL6↓, MCP1↓, PGE2↓, COX2↓, *ROS↓, *antiOx↑, *GPx↑, *Catalase↑, AntiTum↑, TumCP↓, angioG↓, Fas↑, FasL↑, ROS↑, ATM↑, P53↑, RB1↑, Casp9↑, Casp8↑, Casp3↓, BAX↑, Bcl-2↓, Bcl-xL↓, IAP1↓, XIAP↓, survivin↓, MMP2↓, MMP9↓, CycB/CCNB1↓, CDC25↓, CDC25↓, Cyt‑c↑, MMP↓, RenoP↑, mTOR↓, MDM2↓, LC3II↑, ERK↓, COX2↓, MMP3↓, TGF-β↓, EMT↑, ROCK1↓, FAK↓, RAS↓, Rho↓, NF-kB↓, uPA↓, MMP1↓, MMP13↓, ChemoSen↑,
2678- BBR,    Berberine as a Potential Agent for the Treatment of Colorectal Cancer
- Review, CRC, NA
*Inflam↓, *antiOx↑, *cardioP↑, *neuroP↑, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDC2↓, AMPK↝, mTOR↝, Casp8↑, Casp9↑, Cyt‑c↑, TumCMig↓, TumCI↓, EMT↓, MMPs↓, E-cadherin↓, Telomerase↓, *toxicity↓, GRP78/BiP↓, EGFR↓, CDK4↓, COX2↓, PGE2↓, p‑JAK2↓, p‑STAT3↓, MMP2↓, MMP9↓, GutMicro↑, eff↝, *BioAv↓, BioAv↑,
2682- BBR,    Berberine Inhibited Growth and Migration of Human Colon Cancer Cell Lines by Increasing Phosphatase and Tensin and Inhibiting Aquaporins 1, 3 and 5 Expressions
- in-vitro, CRC, HT29 - in-vitro, CRC, SW480 - in-vitro, CRC, HCT116
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, necrosis↑, AQPs↓, PTEN↑, PI3K↓, Akt↓, p‑Akt↓, mTOR↓, p‑mTOR↓,
1102- BBR,    Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma cells
- in-vitro, Melanoma, B16-BL6
TumCMig↓, TumCI↓, EMT↓, p‑PI3K↓, p‑Akt↓, RARα↓, RARβ↑, RARγ↑, E-cadherin↑, N-cadherin↓,
1092- BBR,    Berberine as a Potential Anticancer Agent: A Comprehensive Review
- Review, NA, NA
Apoptosis↑, TumCCA↑, TumAuto↑, TumCI↓, IL1↓, IL6↓, TNF-α↓, LDH↓, P2X7↓, proCasp1↓, Casp1↓, ASC↓,
2742- BetA,    Betulinic acid impairs metastasis and reduces immunosuppressive cells in breast cancer models
- in-vitro, BC, MDA-MB-231 - in-vivo, BC, 4T1 - in-vitro, BC, MCF-7
tumCV↓, TumCMig↓, TumCI↓, STAT3↑, FAK↓, MMPs↓, MMP2↓, MMP9↓, TIMP2↑,
2757- BetA,    Betulinic Acid Inhibits Glioma Progression by Inducing Ferroptosis Through the PI3K/Akt and NRF2/HO-1 Pathways
- in-vitro, GBM, U251
tumCV↓, TumCMig↓, TumCI↓, Apoptosis↑, p‑PI3K↓, p‑Akt↓, Ferroptosis↑, HO-1↑, NRF2↑,
2741- BetA,    Betulinic acid triggers apoptosis and inhibits migration and invasion of gastric cancer cells by impairing EMT progress
- in-vitro, GC, SNU16 - in-vitro, GC, NCI-N87 - in-vivo, NA, NA
TumCG↓, TumCMig↓, TumCI↓, N-cadherin↓, E-cadherin↑, EMT↓, Ki-67↓, MMP2↓,
2719- BetA,    Betulinic Acid Restricts Human Bladder Cancer Cell Proliferation In Vitro by Inducing Caspase-Dependent Cell Death and Cell Cycle Arrest, and Decreasing Metastatic Potential
- in-vitro, CRC, T24 - in-vitro, Bladder, UMUC3 - in-vitro, Bladder, 5637
TumCD↑, Apoptosis↑, TumCCA↑, CycB/CCNB1↓, cycA1/CCNA1↓, CDK2↓, CDC25↓, mtDam↑, BAX↑, cl‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Snail↓, Slug↓, MMP9↓, selectivity↑, MMP↓, ROS∅, TumCMig↓, TumCI↓,
2729- BetA,    Betulinic acid in the treatment of tumour diseases: Application and research progress
- Review, Var, NA
ChemoSen↑, mt-ROS↑, STAT3↓, NF-kB↓, selectivity↑, *toxicity↓, eff↑, GRP78/BiP↑, MMP2↓, P90RSK↓, TumCI↓, EMT↓, MALAT1↓, Glycolysis↓, AMPK↑, Sp1/3/4↓, Hif1a↓, angioG↓, NF-kB↑, NF-kB↓, MMP↓, Cyt‑c↑, Casp9↑, Casp3↑, RadioS↑, PERK↑, CHOP↑, *toxicity↓,
2738- BetA,    Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vivo, NA, NA
TumCI↓, TumCMig↓, Glycolysis↓, lactateProd↓, GRP78/BiP↑, ER Stress↑, PERK↑, p‑eIF2α↑, β-catenin/ZEB1↓, cMyc↓, ROS↑, angioG↓, Sp1/3/4↓, DNAdam↑, TOP1↓, TumMeta↓, MMP2↓, MMP9↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, LDHA↓, p‑PDK1↓, PDK1↓, ECAR↓, OCR↓, Hif1a↓, STAT3↓,
722- Bor,    Boric acid as a promising agent in the treatment of ovarian cancer: Molecular mechanisms
- in-vitro, Ovarian, MDAH-2774
TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, ROS↑, miR-21↓, miR-130a↓, Casp8∅, Casp10∅, cycD1/CCND1∅, CDK6∅, CDK4∅, FADD∅, DR4∅, DR5∅,
1423- Bos,    Acetyl-11-keto-β-Boswellic Acid Suppresses Invasion of Pancreatic Cancer Cells Through The Downregulation of CXCR4 Chemokine Receptor Expression
- in-vitro, Melanoma, U266 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, SkBr3 - in-vitro, PC, PANC1
CXCR4↓, TumCI↓, HER2/EBBR2↓, NF-kB↓,
2767- Bos,    The potential role of boswellic acids in cancer prevention and treatment
- Review, Var, NA
*Inflam↓, AntiCan↑, *MAPK↑, *Ca+2↝, p‑ERK↓, TumCI↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, p‑RB1↓, *NF-kB↓, *TNF-α↓, NF-kB↓, IKKα↓, MCP1↓, IL1α↓, MIP2↓, VEGF↓, Tf↓, COX2↓, MMP9↓, CXCR4↓, VEGF↓, eff↑, PPARα↓, lipid-P?, STAT3↓, TOP1↓, TOP2↑, 5HT↓, p‑PDGFR-BB↓, PDGF↓, AR↓, DR5↑, angioG↓, DR4↑, Casp3↑, Casp8↑, cl‑PARP↑, eff↑, chemoPv↑, Wnt↓, β-catenin/ZEB1↓, ascitic↓, Let-7↑, miR-200b↑, eff↑, MMP1↓, MMP2↓, eff↑, BioAv↓, BioAv↑, Half-Life↓, toxicity↓, Dose↑, BioAv↑, ChemoSen↑,
1263- CAP,    Capsaicin inhibits the migration and invasion via the AMPK/NF-κB signaling pathway in esophagus sequamous cell carcinoma by decreasing matrix metalloproteinase-9 expression
- in-vitro, ESCC, Eca109
TumCMig↓, TumCI↓, MMP9↓, p‑AMPK↑, SIRT1↑, NF-kB↓, p‑IκB↑,
1105- CEL,    Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis
- in-vitro, BC, NA
COX2↓, TumCP↓, TumCMig↓, TumCI↓, EMT↓, miR-145↑, TGF-β↓, SMAD3↓,
1106- CGA,    Chlorogenic Acid Inhibits Epithelial-Mesenchymal Transition and Invasion of Breast Cancer by Down-Regulating LRP6
- vitro+vivo, BC, MCF-7
E-cadherin↑, ZO-1↑, Zeb1↓, N-cadherin↓, Vim↓, Snail↓, Slug↓, MMP2↓, MMP9↓, TumCMig↓, TumCI↓, LRP6↓, p‑LRP6↓, β-catenin/ZEB1↓, TumVol↓, TumW↓,
4489- Chit,  Se,    Inhibiting Metastasis and Improving Chemosensitivity via Chitosan-Coated Selenium Nanoparticles for Brain Cancer Therapy
- in-vitro, GBM, U87MG
TumCG↓, TumCMig↓, TumCI↓, ChemoSen↑, *BBB↑, eff↑, eff↑, eff↑, selectivity↑, MMP2↓, MMP9↓, EPR↑,
3258- CHr,  PBG,    Chrysin Induced Cell Apoptosis and Inhibited Invasion Through Regulation of TET1 Expression in Gastric Cancer Cells
- in-vitro, GC, MKN45
TET1↑, Apoptosis↑, TumCI↓, TumCMig↓,
2590- CHr,    Chrysin suppresses proliferation, migration, and invasion in glioblastoma cell lines via mediating the ERK/Nrf2 signaling pathway
- in-vitro, GBM, T98G - in-vitro, GBM, U251 - in-vitro, GBM, U87MG
TumCP↓, TumCMig↓, TumCI↓, NRF2↓, HO-1↓, NADPH↓, ERK↓,
2786- CHr,    Chemopreventive and therapeutic potential of chrysin in cancer: mechanistic perspectives
- Review, Var, NA
Apoptosis↑, TumCCA↑, angioG↓, TumCI↓, TumMeta↑, *toxicity↓, selectivity↑, chemoPv↑, *GSTs↑, *NADPH↑, *GSH↑, HDAC8↓, Hif1a↓, *ROS↓, *NF-kB↓, SCF↓, cl‑PARP↑, survivin↓, XIAP↓, Casp3↑, Casp9↑, GSH↓, ChemoSen↑, Fenton↑, P21↑, P53↑, cycD1/CCND1↓, CDK2↓, STAT3↓, VEGF↓, Akt↓, NRF2↓,
2787- CHr,    Network pharmacology unveils the intricate molecular landscape of Chrysin in breast cancer therapeutics
- Analysis, Var, MCF-7
TumCP↓, angioG↓, TumCI↓, TumMeta↓, TP53↑, Akt↓, Casp3↑, tumCV↓, TNF-α↓, BioAv↑, BioAv↑, AKT1↓,
1274- Cin,    Cinnamon bark extract suppresses metastatic dissemination of cancer cells through inhibition of glycolytic metabolism
- vitro+vivo, BC, MDA-MB-231
TumCI↓, G6PD↓, HK2↓, Glycolysis↓,
2974- CUR,    Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29 - in-vitro, CRC, HCT15 - in-vitro, CRC, COLO205 - in-vitro, CRC, SW-620 - in-vivo, NA, NA
TumCMig↓, TumCI↓, TumCG↓, TumMeta↓, Sp1/3/4↓, HDAC4↓, FAK↓, CD24↓, E-cadherin↑, EMT↓, TumCP↓, NF-kB↓, AP-1↝, STAT3↓, P53?, β-catenin/ZEB1↓, NOTCH1↝, Hif1a↝, PPARα↝, Rho↓, MMP2↓, MMP9↓,
4709- CUR,    Curcumin Regulates Cancer Progression: Focus on ncRNAs and Molecular Signaling Pathways
- Review, Var, NA
miR-21↓, TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, miR-99↑, JAK↓, STAT↓, cycD1/CCND1↓, P21↑, ChemoSen↑, miR-192-5p↑, cMyc↓, Wnt↓, β-catenin/ZEB1↓, miR-130a↓,
4710- CUR,    Curcumin inhibits migration and invasion of non-small cell lung cancer cells through up-regulation of miR-206 and suppression of PI3K/AKT/mTOR signaling pathway
- in-vitro, Lung, A549
TumCMig↓, TumCI↓, miR-206↑, p‑mTOR↓, p‑Akt↓,
4656- CUR,  EGCG,    Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7
CSCs↓, CD44↓, p‑STAT3↓, NF-kB↓, TumCI↓,
460- CUR,    Curcumin Suppresses microRNA-7641-Mediated Regulation of p16 Expression in Bladder Cancer
- in-vitro, Bladder, T24 - in-vitro, Bladder, TCCSUP - in-vitro, Bladder, J82
miR-7641↓, p16↑, Apoptosis↑, TumCI↓,
461- CUR,    Curcumin inhibits prostate cancer progression by regulating the miR-30a-5p/PCLAF axis
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, miR-30a-5p↑, PCLAF↓, Bcl-2↓, Casp3↓, BAX↑, cl‑Casp3↑,
464- CUR,    Curcumin inhibits the viability, migration and invasion of papillary thyroid cancer cells by regulating the miR-301a-3p/STAT3 axis
- in-vitro, Thyroid, BCPAP - in-vitro, Thyroid, TPC-1
TumCI↓, TumCI↓, MMP2↓, MMP9↓, EMT↓, STAT3↓, miR-301a-3p↓, STAT↓, N-cadherin↓, Vim↓, Fibronectin↓, p‑JAK↓, p‑JAK2↓, p‑JAK3↓, p‑STAT1↓, p‑STAT2↓, E-cadherin↑,
467- CUR,    Curcumin inhibits liver cancer by inhibiting DAMP molecule HSP70 and TLR4 signaling
- in-vitro, Liver, HepG2
TumCP↓, TumCI↓, TumMeta↓, Apoptosis↑, HSP70/HSPA5↓, e-HSP70/HSPA5↓, TLR4↓,
476- CUR,    The effects of curcumin on proliferation, apoptosis, invasion, and NEDD4 expression in pancreatic cancer
- in-vitro, PC, PATU-8988 - in-vitro, PC, PANC1
TumCMig↓, TumCI↓, Apoptosis↑, NEDD9↓, p‑Akt↓, p‑mTOR↓, PTEN↑, p73↑, β-TRCP↑,
456- CUR,    Curcumin Promoted miR-34a Expression and Suppressed Proliferation of Gastric Cancer Cells
- vitro+vivo, GC, SGC-7901
miR-34a↑, TumCP↓, TumCMig↓, TumCI↓, TumCCA↑, Bcl-2↓, CDK4/6↓, cycD1/CCND1↓,
5008- DSF,  Cu,    Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis
- in-vitro, HCC, NA
selectivity↑, TumCD↑, TumCMig↓, TumCI↓, angioG↓, mtDam↑, Iron↑, lipid-P↑, Ferroptosis↑, NF-kB↑, p‑p62↑, Keap1↓, eff↑, eff↓, ChemoSen↑,
4916- DSF,  Cu,    The immunomodulatory function and antitumor effect of disulfiram: paving the way for novel cancer therapeutics
- Review, Var, NA
TumCP↓, TumCMig↓, TumCI↓, eff↑, Imm↑, ROS↑, NF-kB↓, chemoP↑, JNK↑, FOXO↑, Myc↑, TumCCA↑, Apoptosis↑, RadioS↑, PD-L1↑, eff↑, CSCs↓, Dose↝, Half-Life↑,
1621- EA,    The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumMeta↓, TumCI↓, TumAuto↑, VEGFR2↓, MAPK↓, PI3K↓, Akt↓, PD-1↓, NOTCH↓, PCNA↓, Ki-67↓, cycD1/CCND1↓, CDK2↑, CDK6↓, Bcl-2↓, cl‑PARP↑, BAX↑, Casp3↑, DR4↑, DR5↑, Snail↓, MMP2↓, MMP9↓, TGF-β↑, PKCδ↓, β-catenin/ZEB1↓, SIRT1↓, HO-1↓, ROS↑, CHOP↑, Cyt‑c↑, MMP↓, OCR↓, AMPK↑, Hif1a↓, NF-kB↓, E-cadherin↑, Vim↓, EMT↓, LC3II↑, CIP2A↓, GLUT1↓, PDH↝, MAD↓, LDH↓, GSTs↑, NOTCH↓, survivin↓, XIAP↓, ER Stress↑, ChemoSideEff↓, ChemoSen↑,
1618- EA,    A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action
- Review, BC, NA
TumCCA↑, TumCMig↓, TumCI↓, TumMeta↓, Apoptosis↑, TGF-β↓, SMAD3↓, CDK6↓, PI3K↓, Akt↓, angioG↓, VEGFR2↓, MAPK↓, NEDD9↓, NF-kB↓, eff↑, eff↑, RadioS↑, ChemoSen↑, DNAdam↑, eff↑, *toxicity∅, *toxicity∅,
1111- EDM,    Evodiamine exerts inhibitory roles in non‑small cell lung cancer cell A549 and its sub‑population of stem‑like cells
- in-vitro, Lung, A549
TumCP↓, TumCMig↓, TumCI↓, EMT↓,
1072- EGCG,    Epigallocatechin gallate (EGCG) suppresses epithelial-Mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways
- in-vitro, Thyroid, 8505C
EMT↓, TumCI↓, TumCMig↓, TGF-β↓, p‑SMAD2↓, p‑SMAD3↓, SMAD4↓,
651- EGCG,    Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications
ROS↑, p‑AMPK↑, mTOR↓, FAK↓, Smo↓, Gli1↓, HH↓, TumCMig↓, TumCI↓, NOTCH↓, JAK↓, STAT↓, Bcl-2↓, Bcl-xL↓, BAX↑, Casp9↑,
665- EGCG,    Anticancer effects of epigallocatechin-3-gallate nanoemulsion on lung cancer cells through the activation of AMP-activated protein kinase signaling pathway
- in-vitro, NA, H1299
AMPK↑, TumCP↓, TumCMig↓, TumCI↓,
688- EGCG,  GEM,    Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial–Mesenchymal Transition: Enhanced Efficacy When Combined with Gemcitabine
- in-vitro, PC, NA
Zeb1↓, β-catenin/ZEB1↓, Vim↓, Akt↓, p‑IGFR↓, TumCG↓, TumCMig↓, TumCI↓,
4685- EGCG,    Epigallocathechin gallate, polyphenol present in green tea, inhibits stem-like characteristics and epithelial-mesenchymal transition in nasopharyngeal cancer cell lines
- in-vitro, NPC, TW01 - in-vitro, NPC, TW06
CSCs↓, EMT↓, TumCMig↓, TumCI↓, OCT4↓, Snail↓, Vim↓, E-cadherin↓, HSP70/HSPA5↓, HSP90↓, AntiTum↓,
1503- EGCG,    Epigenetic targets of bioactive dietary components for cancer prevention and therapy
- Review, NA, NA
selectivity↑, DNMT1↓, RECK↑, MMPs↓, TumCI↓, angioG↓, TumMeta↓, HATs↓, IκB↑, NF-kB↓, IL6↓, COX2↓, NOS2↓, ac‑H3↑, ac‑H4↑, eff↑,
1319- EMD,    Emodin treatment of papillary thyroid cancer cell lines in vitro inhibits proliferation and enhances apoptosis via downregulation of NF‑κB and its upstream TLR4 signaling
- in-vitro, Thyroid, TPC-1 - in-vitro, Thyroid, IHH4
NF-kB↓, TLR4↓, TumCI↓, TumCMig↓,
1247- EMD,    Emodin exerts antitumor effects in ovarian cancer cell lines by preventing the development of cancer stem cells via epithelial mesenchymal transition
- vitro+vivo, Ovarian, SKOV3 - in-vitro, Ovarian, A2780S
TumCP↓, TumCMig↓, TumCI↓, EMT↓, N-cadherin↓, Vim↓, E-cadherin↑, TumCG↓, CD133↓, OCT4↓, CSCs↓,
1654- FA,    Molecular mechanism of ferulic acid and its derivatives in tumor progression
- Review, Var, NA
AntiCan↑, Inflam↓, RadioS↑, ROS↑, Apoptosis↑, TumCCA↑, TumCMig↑, TumCI↓, angioG↓, ChemoSen↑, ChemoSideEff↓, P53↑, cycD1/CCND1↓, CDK4↓, CDK6↓, TumW↓, miR-34a↑, Bcl-2↓, Casp3↑, BAX↑, β-catenin/ZEB1↓, cMyc↓, Bax:Bcl2↑, SOD↓, GSH↓, LDH↓, ERK↑, eff↑, JAK2↓, STAT6↓, NF-kB↓, PYCR1↓, PI3K↓, Akt↓, mTOR↓, Ki-67↓, VEGF↓, FGFR1↓, EMT↓, CAIX↓, LC3II↑, p62↑, PKM2↓, Glycolysis↓, *BioAv↓,
1113- FIS,    Fisetin suppresses migration, invasion and stem-cell-like phenotype of human non-small cell lung carcinoma cells via attenuation of epithelial to mesenchymal transition
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
TumCI↓, TumCMig↓, EMT↓, E-cadherin↑, ZO-1↑, Vim↓, N-cadherin↓, MMP2↓, CD44↓, CD133↓, β-catenin/ZEB1↓, NF-kB↓, EGFR↓, STAT3↓, CSCs↓,
2850- FIS,    Fisetin regulates TPA-induced breast Cancer cell invasion by suppressing matrix metalloproteinase-9 activation via the PKC/ROS/MAPK pathways
- in-vitro, BC, MCF-7
TumCI↓, PKCδ↓, ROS↓, ERK↑, p38↓, NF-kB↓, MMP9↓,
2847- FIS,    Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells
- in-vitro, CCA, NA
tumCV↓, ChemoSen↑, TumCMig↓, ROS↑, TumCI↓, angioG↓, CDK2↓, PI3K↓, Akt↓, mTOR↓, EGFR↓, Casp↑, mTORC1↓, mTORC2↑, cycD1/CCND1↓, cycE/CCNE↓, MMP2↓, MMP9↓, ER Stress↑, Ca+2↑, eff↓,
2824- FIS,    Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics
- Review, Var, NA
*antiOx↑, *Inflam↓, angioG↓, BioAv↓, BioAv↑, TumCP↓, TumCI↓, TumCMig↓, *neuroP↑, EMT↓, ROS↑, selectivity↑, EGFR↓, NF-kB↓, VEGF↓, MMP9↓, MMP↓, cl‑PARP↑, Casp7↑, Casp8↑, Casp9↑, *ROS↓, uPA↓, MMP1↓, Wnt↓, Akt↓, PI3K↓, ERK↓, Half-Life↝,
2829- FIS,    Fisetin: An anticancer perspective
- Review, Var, NA
TumCP↓, TumCI↓, TumCCA↑, TumCG↓, Apoptosis↑, cl‑PARP↑, PKCδ↓, ROS↓, ERK↓, NF-kB↓, survivin↓, ROS↑, PI3K↓, Akt↓, mTOR↓, MAPK↓, p38↓, HER2/EBBR2↓, EMT↓, PTEN↑, HO-1↑, NRF2↑, MMP2↓, MMP9↓, MMP↓, Casp8↑, Casp9↑, TRAILR↑, Cyt‑c↑, XIAP↓, P53↑, CDK2↓, CDK4↓, CDC25↓, CDC2↓, VEGF↓, DNAdam↑, TET1↓, CHOP↑, CD44↓, CD133↓, uPA↓, CSCs↓,
2839- FIS,    Dietary flavonoid fisetin for cancer prevention and treatment
- Review, Var, NA
DNAdam↑, ROS↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp9↑, cl‑Casp3↑, Cyt‑c↑, lipid-P↓, TumCG↓, TumCA↓, TumCMig↓, TumCI↓, uPA↓, ERK↓, MMP9↓, NF-kB↓, cFos↓, cJun↓, AP-1↓, TumCCA↑, AR↓, mTORC1↓, mTORC2↓, TSC2↑, EGF↓, TGF-β↓, EMT↓, P-gp↓, PI3K↓, Akt↓, mTOR↓, eff↑, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, ChemoSen↑, CDK2↓, CDK4↓, cycE/CCNE↓, cycD1/CCND1↓, P21↑, COX2↓, Wnt↓, EGFR↓, β-catenin/ZEB1↓, TCF-4↓, MMP7↓, RadioS↑, eff↑,
1969- GamB,    Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells
- in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
AntiTum↑, TumCI↓, Apoptosis↑, ROS↑, Cyt‑c↑, Akt↓, mTOR↓, TumCG↓, TumMeta↓,
830- GAR,    Garcinol modulates tyrosine phosphorylation of FAK and subsequently induces apoptosis through down-regulation of Src, ERK, and Akt survival signaling in human colon cancer cells
- in-vitro, CRC, HT-29
TumCI↓, TumCMig↓, Apoptosis↑, p‑FAK↓, Src↓, MAPK↓, ERK↓, PI3K/Akt↓, Bax:Bcl2↑, Cyt‑c↑, MMP7↓,
817- GAR,    Garcinol inhibits esophageal cancer metastasis by suppressing the p300 and TGF-β1 signaling pathways
- vitro+vivo, SCC, KYSE150 - vitro+vivo, SCC, KYSE450
HATs↓, TumCCA↑, Apoptosis↑, TumCMig↓, TumCI↓, CBP↓, p300↓, TGF-β↓, Ki-67↓, SMAD2↓, SMAD3↓,
814- GAR,  PacT,    Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA2 and NF-κB/Twist1 signaling pathways in a mouse 4T1 breast tumor model
- in-vivo, BC, NA
Apoptosis↑, TumCCA↑, EMT↓, TumCI↓,
812- GAR,    Anti-proliferative and anti-invasive effects of garcinol from Garcinia indica on gallbladder carcinoma cells
- in-vitro, Gall, GBC-SD - in-vitro, Gall, NOZ
TumCG↓, TumCI↓, MMP2↓, MMP9↓,
806- GAR,    Garcinol exerts anti-cancer effect in human cervical cancer cells through upregulation of T-cadherin
- vitro+vivo, Pca, HeLa - vitro+vivo, Cerv, SiHa
TumCI↓, TumCMig↓, TumCCA↑, Apoptosis↑, T-cadherin↑,
802- GAR,    Garcinol acts as an antineoplastic agent in human gastric cancer by inhibiting the PI3K/AKT signaling pathway
- in-vitro, GC, HGC27
TumCP↓, TumCI↓, Apoptosis↑, PI3K/Akt↓, Akt↓, p‑mTOR↓, cycD1/CCND1↓, MMP2↓, MMP9↓, BAX↑, Bcl-2↓,
1186- Gb,    Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis
- in-vitro, PC, NA - in-vitro, Nor, HUVECs - in-vivo, PC, NA
tumCV↓, *toxicity∅, TumCMig↓, TumCI↓, Apoptosis↑, AMPK↑, lipoGen↓, ACC↓, FASN↓,
1189- Gb,    New insight into the mechanisms of Ginkgo biloba leaves in the treatment of cancer
- Review, NA, NA
Apoptosis↑, TumCP↓, TumCI↓, TumCMig↓, Inflam↓, antiOx↑, angioG↓,
1118- Ge,    Grape Seed Proanthocyanidins Inhibit Migration and Invasion of Bladder Cancer Cells by Reversing EMT through Suppression of TGF- β Signaling Pathway
- in-vitro, Bladder, T24 - in-vitro, Bladder, 5637
TumCMig↓, TumCI↓, MMP2↓, MMP9↓, EMT↓, N-cadherin↓, Vim↓, Slug↓, E-cadherin↑, ZO-1↑, p‑SMAD2↓, p‑SMAD3↓, p‑Akt↓, p‑ERK↓, p‑p38↓,
1240- Ge,  PACs,    Grape Seed Proanthocyanidins Inhibit Melanoma Cell Invasiveness by Reduction of PGE2 Synthesis and Reversal of Epithelial-to-Mesenchymal Transition
- in-vitro, Melanoma, A375 - in-vitro, Melanoma, Hs294T
TumCMig↓, TumCI↓, COX2↓, PGE2↓, NF-kB↓, EMT↓, E-cadherin↑, Vim↓, Fibronectin↓, N-cadherin↓,
2998- GEN,    Cellular and Molecular Mechanisms Modulated by Genistein in Cancer
- Review, Var, NA
Hif1a↓, VEGF↓, PDGF↓, uPA↓, MMP2↓, MMP9↓, chemoPv↑, TumCI↓, TumMeta↓, NF-kB↓, AP-1↓, IKKα↓, PI3K↓, Akt↓, EMT↓, CSCs↓,
4505- GLA,    Gamma linolenic acid suppresses hypoxia-induced proliferation and invasion of non-small cell lung cancer cells by inhibition of HIF1α
- in-vitro, NSCLC, Calu-1
TumCP↓, PCNA↓, Ki-67↓, MCM2↓, Bcl-2↓, BAX↑, cl‑Casp3↑, TumCMig↓, TumCI↓, Hif1a↓, VEGF↓,
844- Gra,    Annona muricata Leaf Extract Triggered Intrinsic Apoptotic Pathway to Attenuate Cancerous Features of Triple Negative Breast Cancer MDA-MB-231 Cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7
tumCV↓, TumCI↓, ROS↑,
858- Gra,    Annona muricata leaves induce G₁ cell cycle arrest and apoptosis through mitochondria-mediated pathway in human HCT-116 and HT-29 colon cancer cells
- in-vitro, CRC, HT-29 - in-vitro, CRC, HCT116
TumCCA↑, Apoptosis↑, ROS↑, MMP↓, Cyt‑c↑, Casp↑, BAX↑, Bcl-2↓, TumCMig↓, TumCI↓,
2511- H2,    Molecular hydrogen suppresses glioblastoma growth via inducing the glioma stem-like cell differentiation
- in-vivo, GBM, U87MG
TumCG↓, OS↑, CD133↓, Ki-67↓, angioG↓, Diff↑, TumCMig↓, TumCI↓, Dose↝, BBB↑, mt-ROS↑,
1643- HCAs,    Mechanisms involved in the anticancer effects of sinapic acid
- Review, Var, NA
*BioAv↓, *toxicity↓, Dose∅, ROS⇅, ROS↑, Igs↑, TumCCA↑, TumAuto↑, eff↑, angioG↓, TumCI↓, TumMeta↓, EMT↓, Vim↓, MMP9↓, MMP2↓, Snail↓, E-cadherin↑, p‑Akt↓, GSK‐3β↓, TumCP↓, ChemoSen↑,
1153- HNK,    Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor
- in-vitro, GBM, U251 - in-vitro, GBM, U87MG - in-vivo, NA, NA
tumCV↓, Apoptosis↑, TumCMig↓, TumCI↓, Bcl-2↓, EGFR↓, CD133↓, Nestin↓, Akt↓, ERK↓, Casp3↑, p‑STAT3↓, TumCG↓,
2881- HNK,    Honokiol Suppressed Pancreatic Cancer Progression via miR-101/Mcl-1 Axis
- in-vitro, PC, PANC1
tumCV↓, Casp3↑, Apoptosis↑, TumCCA↑, TumCI↓, Mcl-1↓, EMT↓,
2882- HNK,    Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling
- in-vitro, PC, PANC1
TumCI↓, TumCMig↓, p‑SMAD2↓, p‑SMAD3↓, EMT↓, N-cadherin↓, Vim↓, E-cadherin↑, Snail↓, Slug↓, Rho↓, ROCK1↓,
2885- HNK,    Honokiol: a novel natural agent for cancer prevention and therapy
NF-kB↓, STAT3↓, EGFR↓, mTOR↓, BioAv↝, Inflam↓, TumCP↓, angioG↓, TumCI↓, TumMeta↓, cSrc↓, JAK1↓, JAK2↓, ERK↓, Akt↓, PTEN↑, ChemoSen↑, chemoP↑, COX2↓, PGE2↓, TNF-α↓, IL1β↓, IL6↓, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, DNAdam↑, Cyt‑c↑, RadioS↑, RAS↓, BBB↑, BioAv↓, Half-Life↝, Half-Life↝, toxicity↓,
2897- HNK,    Honokiol Inhibits Proliferation, Invasion and Induces Apoptosis Through Targeting Lyn Kinase in Human Lung Adenocarcinoma Cells
- in-vitro, Lung, PC9 - in-vitro, Lung, A549
TumCP↓, Apoptosis↑, EGFR↓, PI3K↓, Akt↓, STAT3↓, TumCI↓, TNF-α↑, NF-kB↓, VEGF↓, MMP9↓, COX2↓,
2898- HNK,    Honokiol Suppression of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Cell Biological Activity and Its Mechanism
- in-vitro, GC, AGS - in-vitro, GC, NCI-N87 - in-vitro, BC, MGC803 - in-vitro, GC, SGC-7901
TumCP↓, Apoptosis↑, TumCI↓, TumCMig↓, HER2/EBBR2↓, TumCCA↑, PI3K↓, Akt↓, MMP9↓, P21↑,
2864- HNK,    Honokiol: A Review of Its Anticancer Potential and Mechanisms
- Review, Var, NA
TumCCA↑, CDK2↓, EMT↓, MMPs↓, AMPK↑, TumCI↓, TumCMig↓, TumMeta↓, VEGFR2↓, *antiOx↑, *Inflam↓, *BBB↑, *neuroP↑, *ROS↓, Dose↝, selectivity↑, Casp3↑, Casp9↑, NOTCH1↓, cycD1/CCND1↓, cMyc↓, P21?, DR5↑, cl‑PARP↑, P53↑, Mcl-1↑, p65↓, NF-kB↓, ROS↑, JNK↑, NRF2↑, cJun↑, EF-1α↓, MAPK↓, PI3K↓, mTORC1↓, CSCs↓, OCT4↓, Nanog↓, SOX4↓, STAT3↓, CDK4↓, p‑RB1↓, PGE2↓, COX2↓, β-catenin/ZEB1↑, IKKα↓, HDAC↓, HATs↑, H3↑, H4↑, LC3II↑, c-Raf↓, SIRT3↑, Hif1a↓, ER Stress↑, GRP78/BiP↑, cl‑CHOP↑, MMP↓, PCNA↓, Zeb1↓, NOTCH3↓, CD133↓, Nestin↓, ATG5↑, ATG7↑, survivin↓, ChemoSen↑, SOX2↓, OS↑, P-gp↓, Half-Life↓, Half-Life↝, eff↑, BioAv↓,
2868- HNK,    Honokiol: A review of its pharmacological potential and therapeutic insights
- Review, Var, NA - Review, Sepsis, NA
*P-gp↓, *ROS↓, *TNF-α↓, *IL10↓, *IL6↓, eIF2α↑, CHOP↑, GRP78/BiP↑, BAX↑, cl‑Casp9↑, p‑PERK↑, ER Stress↑, Apoptosis↑, MMPs↓, cFLIP↓, CXCR4↓, Twist↓, HDAC↓, BMPs↑, p‑STAT3↓, mTOR↓, EGFR↓, NF-kB↓, Shh↓, VEGF↓, tumCV↓, TumCMig↓, TumCI↓, ERK↓, Akt↓, Bcl-2↓, Nestin↓, CD133↓, p‑cMET↑, RAS↑, chemoP↑, *NRF2↑, *NADPH↓, *p‑Rac1↓, *ROS↓, *IKKα↑, *NF-kB↓, *COX2↓, *PGE2↓, *Casp3↓, *hepatoP↑, *antiOx↑, *GSH↑, *Catalase↑, *RenoP↑, *ALP↓, *AST↓, *ALAT↓, *neuroP↑, *cardioP↑, *HO-1↑, *Inflam↓,
2874- HNK,    Suppressing migration and invasion of H1299 lung cancer cells by honokiol through disrupting expression of an HDAC6‐mediated matrix metalloproteinase 9
- in-vitro, Lung, H1299
MMP9↓, α-tubulin↑, TumCI↓, HDAC6↓, HSP90↓, TumCMig↓, EGFR↓,
2878- HNK,    Suppressing migration and invasion of H1299 lung cancer cells by honokiol through disrupting expression of an HDAC6-mediated matrix metalloproteinase 9
- in-vitro, Lung, H1299
TumCMig↓, TumCI↓, MMP9↓, α-tubulin↑, HDAC6↓, HSP90↓,
4632- HT,    Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/β-catenin and TGFβ signaling pathways
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vitro, BC, SUM159
CSCs↓, TumCMig↓, TumCI↓, β-catenin/ZEB1↓, Wnt↓, p‑LRP6↓, LRP6↓, cycD1/CCND1↓, EMT↓, Slug↓, Zeb1↓, Snail↓, Vim↓, SMAD2↓, SMAD3↓, TGF-β↓,
4640- HT,    The anti-cancer potential of hydroxytyrosol
- Review, Var, NA
selectivity↑, MMP↓, Cyt‑c↑, Casp9↑, Casp3↑, Bcl-2↓, BAX↑, MPT↑, Fas↑, PI3K↓, Akt↓, mTOR↓, Mcl-1↓, survivin↓, STAT3↓, EMT↓, TumCI↓, angioG↓, E-cadherin↑, N-cadherin↓, Snail↓, Twist↓, MMPs↓, MMP2↓, MMP9↓, VEGF↓, VEGFR2↓, Hif1a↓, CSCs↓, CD44↓, Wnt↓, β-catenin/ZEB1↓,
974- JG,    Juglone down-regulates the Akt-HIF-1α and VEGF signaling pathways and inhibits angiogenesis in MIA Paca-2 pancreatic cancer in vitro
- in-vitro, PC, MIA PaCa-2
Hif1a↓, VEGF↓, p‑Akt↓, TumCP↓, TumCI↓,
1924- JG,    Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway
- in-vitro, Lung, A549
TumCMig↓, TumCI↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, BAX↑, Cyt‑c↑, ROS↑, MDA↑, GPx4↓, SOD↓, PI3K↓, Akt↓, eff↓,
4687- LT,  QC,    Dietary Flavonoids Luteolin and Quercetin Suppressed Cancer Stem Cell Properties and Metastatic Potential of Isolated Prostate Cancer Cells
- in-vitro, Pca, DU145
CSCs↓, EMT↓, MMPs↓, TumCMig↓, TumCI↓,
3275- Lyco,    Multifaceted Effects of Lycopene: A Boulevard to the Multitarget-Based Treatment for Cancer
- Review, Var, NA
TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, P21↑, P53↑, GSK‐3β↓, p27↓, Akt↓, mTOR↓, ROS↓, MMPs↓, TumCI↓, TumCMig↓, NF-kB↓, *iNOS↓, *COX2↓, lipid-P↓, GSH↑, NRF2↑,
3262- Lyco,    Lycopene inhibits matrix metalloproteinase-9 expression and down-regulates the binding activity of nuclear factor-kappa B and stimulatory protein-1
- in-vitro, adrenal, SK-HEP-1
TumCI↓, MMP9↓, NF-kB↓, Sp1/3/4↓, IGF-1R↓, i-ROS↓,
4782- Lyco,    New Insights into Molecular Mechanism behind Anti-Cancer Activities of Lycopene
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, TumCI↓, TumCA↓, ROS↓, MMP2↓, MMP7↓, MMP9↓, VEGF↓, E-cadherin↑, TIMP1↑, TIMP2↑, BioAv↝, *IL12↓, *TNF-α↓, *IL1↓, *IL1β↓, *IL6↓, COX2↓, iNOS↓, *radioP↑, NF-kB↓, survivin↓, Casp3↑, Bax:Bcl2↑,
4791- Lyco,    Investigating into anti-cancer potential of lycopene: Molecular targets
- Review, Var, NA
*antiOx↑, TumCP↓, TumCCA↓, Apoptosis↑, TumCI↓, angioG↓, TumMeta↓, *Risk↓, cycD1/CCND1↓, CycD3↓, cycE/CCNE↓, CDK2↓, CDK4↓, Bcl-2↓, P21↑, p27↑, P53↑, BAX↑, selectivity↑, MMP↓, Cyt‑c↑, Wnt↓, eff↑, PPARγ↑, LDL↓, Akt↓, PI3K↓, mTOR↓, PDGF↓, NF-kB↓, eff↑,
1126- Lyco,    Lycopene Inhibits Epithelial–Mesenchymal Transition and Promotes Apoptosis in Oral Cancer via PI3K/AKT/m-TOR Signal Pathway
- vitro+vivo, Oral, NA
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, EMT↓, PI3K↓, Akt↓, mTOR↓, E-cadherin↓, BAX↑, N-cadherin↓, p‑PI3K↓, p‑Akt↓, p‑mTOR↓, Bcl-2↓,
1196- MAG,    2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression
- in-vitro, HCC, NA
TumCG↓, TumCMig↓, TumCI↓, TumCCA↑, HDAC↓,
4535- MAG,  5-FU,    Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervical cancer cells by targeting PI3K/AKT/mTOR and EMT pathways
- in-vitro, Cerv, NA
ChemoSen↑, TumCP↓, vinculin↓, TumCA↓, TumCMig↓, TumCI↓, p‑Akt↓, p‑PI3K↓, mTOR↓, E-cadherin↑, β-catenin/ZEB1↑, Snail↓, Slug↓,
4531- MAG,    Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway
- in-vitro, CRC, HCT116
Apoptosis↑, DNAdam↑, Casp3↑, cl‑PARP↑, p‑AMPK↑, Bcl-2↓, P53↑, BAX↑, Cyt‑c↑, TumCMig↓, TumCI↓,
4528- MAG,    Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update
- Review, Nor, NA
*Inflam↑, *cardioP↑, *angioG↓, *antiOx↑, *neuroP↑, *Bacteria↓, AntiTum↑, TumCG↓, TumCMig↓, TumCI↓, Apoptosis↑, E-cadherin↑, NF-kB↓, TumCCA↑, cycD1/CCND1↓, PCNA↓, Ki-67↓, MMP2↓, MMP7↓, MMP9↓, TumCG↓, Casp3↑, NF-kB↓, Akt↓, mTOR↓, LDH↓, Ca+2↑, eff↑, *toxicity↓, *BioAv↝, *PGE2↓, *TLR2↓, *TLR4↓, *MAPK↓, *PPARγ↓,
4520- MAG,    Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling
- vitro+vivo, PC, PANC1
Vim↓, E-cadherin↑, EMT↓, N-cadherin↓, p‑SMAD2↓, p‑SMAD3↓, TumCP↓, TumCMig↓, TumCI↓, TGF-β↓,
2384- MET,    Integration of metabolomics and transcriptomics reveals metformin suppresses thyroid cancer progression via inhibiting glycolysis and restraining DNA replication
- in-vitro, Thyroid, BCPAP - in-vivo, NA, NA - in-vitro, Thyroid, TPC-1
Glycolysis↓, OXPHOS↑, tumCV↓, TumCI↓, TumCMig↓, EMT↓, Apoptosis↑, TumCCA↑, LDHA↓, PKM2↓, IDH1↑, TumCG↓,
2387- MET,  GEM,    Metformin Increases the Response of Cholangiocarcinoma Cells to Gemcitabine by Suppressing Pyruvate Kinase M2 to Activate Mitochondrial Apoptosis
- in-vitro, CCA, HCC9810
eff↑, tumCV↓, TumCMig↓, TumCI↓, Apoptosis↑, PKM2↓, PDHB↓,
2378- MET,    Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway
- in-vitro, SCC, CAL27 - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, EMT↓, mTOR↓, Hif1a↓, PKM2↓, STAT3↓, E-cadherin↑, Vim↓, Snail↓, STAT3↓,
2375- MET,    Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling
- in-vitro, GC, SGC-7901
tumCV↓, TumCI↓, TumCMig↓, Apoptosis↑, PARP↓, PI3K↓, Akt↓, Hif1a↓, PKM2↓, COX2↓,
970- MET,    Metformin suppresses HIF-1α expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer
CAFs/TAFs↝, p‑AMPK↑, PHDs↑, Hif1a↓, TumCI↓,
4354- MF,  doxoR,    Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach
- in-vivo, BC, MDA-MB-231 - in-vivo, BC, MCF-7
selectivity↑, Apoptosis↑, TumCI↓, tumCV↓, TumVol↓, eff↓, eff↑, ROS↑, Ca+2↑, TumCMig↓,
3478- MF,    One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study
- Trial, BC, NA - in-vitro, BC, MCF-7 - in-vitro, Nor, C2C12
TumCP↓, TumCMig↓, TumCI↓, *toxicity∅, TGF-β↓, Twist↓, Slug↓, β-catenin/ZEB1↓, Vim↓, p‑SMAD2↓, p‑SMAD3↓, angioG↓, VEGF↓, selectivity↑, LIF↑,
3500- MF,    Moderate Static Magnet Fields Suppress Ovarian Cancer Metastasis via ROS-Mediated Oxidative Stress
- in-vitro, Ovarian, SKOV3
ROS↑, CSCs↓, CD44↓, SOX2↓, cMyc↓, TumMeta↓, TumCI↓, TumCMig↓, CD133↓, Nanog↓,
3470- MF,    Pulsed electromagnetic fields inhibit IL-37 to alleviate CD8+ T cell dysfunction and suppress cervical cancer progression
- in-vitro, Cerv, HeLa
TNF-α↑, IL6↑, ROS↑, Apoptosis↑, TumCP↓, TumCMig↓, TumCI↓,
205- MFrot,  MF,    Intermittent F-actin Perturbations by Magnetic Fields Inhibit Breast Cancer Metastasis
- vitro+vivo, BC, MDA-MB-231
OS↑, F-actin↓, TumCI↓, TumCMig↓, Rho↓, selectivity↑,
516- MFrot,  immuno,  MF,    Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth
- vitro+vivo, GBM, U87MG
TumCP↓, Apoptosis↑, TumCMig↓, ROS↑, PD-L1↑, TumVol↓, eff↑, *toxicity∅, eff↑, *toxicity∅, Dose↝, tumCV↓, TumCI↓,
4976- Nimb,    Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition
- vitro+vivo, PC, NA
ROS↑, Apoptosis↑, TumAuto↑, TumCP↓, TumCMig↓, TumCI↓, EMT↓, Dose↓, selectivity↑, Akt↓, eff↓, BAX↑, cl‑Casp3↑, cl‑PARP↑, Bcl-2↓,
4971- Nimb,    Nimbolide, a Neem Limonoid, Is a Promising Candidate for the Anticancer Drug Arsenal
- Review, Var, NA
TumCP↓, Apoptosis↓, TumCI↓, angioG↓, TumMeta↓, Inflam↓,
1911- Nos,    Noscapine inhibits tumor growth in TMZ-resistant gliomas
- in-vitro, GBM, NA - in-vivo, GBM, NA
TumCG↓, TumCI↓, OS↑,
1130- OA,    Oroxylin A Suppresses the Cell Proliferation, Migration, and EMT via NF-κB Signaling Pathway in Human Breast Cancer Cells
- in-vitro, BC, MDA-MB-231
TumCP↓, TumCI↓, TumCMig↓, E-cadherin↑, N-cadherin↓, Vim↓, NF-kB↓,
4628- OLE,    Effects of oleuropein on tumor cell growth and bone remodelling: Potential clinical implications for the prevention and treatment of malignant bone diseases
- in-vitro, Var, NA
chemoPv↑, TumCP↓, angioG↓, TumCI↓, TumMeta↓,
1225- OLST,    Orlistat Induces Ferroptosis in Pancreatic Neuroendocrine Tumors by Inactivating the MAPK Pathway
- vitro+vivo, PC, NA
TumCMig↓, TumCI↓, Ferroptosis↑, MAPK↓,
2381- PBG,    Chinese Poplar Propolis Inhibits MDA-MB-231 Cell Proliferation in an Inflammatory Microenvironment by Targeting Enzymes of the Glycolytic Pathway
- in-vitro, BC, MDA-MB-231
TumCP↓, TumCMig↓, TumCI↓, angioG↓, TNF-α↓, IL1β↓, IL6↓, NLRP3↓, Glycolysis↓, HK2↓, PFK↓, PKM2↓, LDHA↓, ROS↑, MMP↓,
1231- PBG,    Caffeic acid phenethyl ester inhibits MDA-MB-231 cell proliferation in inflammatory microenvironment by suppressing glycolysis and lipid metabolism
- in-vitro, BC, MDA-MB-231
TumCP↓, TumCMig↓, TumCI↓, MMP↓, TLR4↓, TNF-α↓, NF-kB↓, IL1β↓, IL6↓, IRAK4↓, GLUT1↓, GLUT3↓, HK2↓, PFK↓, PKM2↓, LDHA↓, ACC↓, FASN↓, eff↓,
4931- PEITC,    Phenethyl isothiocyanate (PEITC) suppresses prostate cancer cell invasion epigenetically through regulating microRNA-194
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3
Risk↓, miR-194↑, TumCI↓, MMP2↓, MMP9↓, BMP2↓, *chemoPv↑,
4933- PEITC,    Phenethyl isothiocyanate inhibits metastasis potential of non-small cell lung cancer cells through FTO mediated TLE1 m6A modification
- vitro+vivo, Lung, H1299 - vitro+vivo, SCC, H226
AntiCan↓, TumCP↓, TumMeta↓, ChemoSen↑, tumCV↓, TumCI↓, TumCMig↓, FTO↓, TLE1↓, Akt↓, NF-kB↓,
4926- PEITC,    PEITC inhibits the invasion and migration of colorectal cancer cells by blocking TGF-β-induced EMT
- in-vitro, CRC, SW48
TumCI↓, TumCMig↓, EMT↓, Smad1↓, AntiCan↑, Snail↓, Slug↓, Zeb1↓, ZEB2↓, TGF-β1↓, eff↑, E-cadherin↑, N-cadherin↓, Vim↓,
4922- PEITC,    Phenethyl Isothiocyanate: A comprehensive review of anti-cancer mechanisms
- Review, Var, NA
Risk↓, AntiCan↑, TumCP↓, TumMeta↓, ChemoSen↑, *BioAv↑, *other↝, *Dose↝, Dose↓, *BioAv↑, *Dose↝, *Half-Life↝, *toxicity↝, GSH↓, ROS↑, CYP1A1↑, CYP1A2↑, P450↓, CYP2E1↑, CYP3A4↓, CYP2A3/CYP2A6↓, *ROS↓, *GPx1↑, *SOD1↑, *SOD2↑, Akt↓, EGFR↓, HER2/EBBR2↓, P53↑, Telomerase↓, selectivity↑, MMP↓, Cyt‑c↑, Apoptosis↑, DR4↑, Fas↑, XIAP↓, survivin↓, TumAuto↑, Hif1a↓, angioG↓, MMPs↓, ERK↓, NF-kB↓, EMT↓, TumCI↓, TumCMig↓, Glycolysis↓, ATP↓, selectivity↑, *antiOx↑, Dose↝, other↝, OCR↓, GSH↓, ITGB1↓, ITGB6↓, ChemoSen↑,
1256- PI,    Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models
- in-vitro, adrenal, PHEO - in-vivo, NA, NA
Apoptosis↑, ROS↑, TumCMig↓, TumCI↓, EMT↓, angioG↓, Necroptosis↑, MAPK↑, ERK↑,
1131- PI,    Piperlongumine‑loaded nanoparticles inhibit the growth, migration and invasion and epithelial‑to‑mesenchymal transition of triple‑negative breast cancer cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549
TumCG↓, tumCV↓, TumCMig↓, TumCI↓, MMP2↓, Slug↓, N-cadherin↓, β-catenin/ZEB1↓, SMAD3↓, E-cadherin↑, EMT↓,
1939- PL,    Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP
- in-vitro, HCC, HepG2 - in-vitro, HCC, HUH7 - in-vivo, NA, NA
TumCMig↓, TumCI↓, ER Stress↑, selectivity↑, tumCV↓, ROS↑, GSH↓, eff↓, Ca+2↑, MAPK↑, CHOP↑, Dose↝,
2961- PL,    Piperlongumine inhibits esophageal squamous cell carcinoma in vitro and in vivo by triggering NRF2/ROS/TXNIP/NLRP3-dependent pyroptosis
- in-vitro, ESCC, KYSE-30
Pyro↑, TumCP↓, TumCMig↓, TumCI↓, ASC↑, cl‑Casp1↑, NLRP3↑, GSDMD↑, ROS↑, NRF2↓, TXNIP↑,
2952- PL,    Piperlongumine suppresses bladder cancer invasion via inhibiting epithelial mesenchymal transition and F-actin reorganization
- in-vitro, Bladder, T24 - in-vivo, Bladder, NA
TumCP↓, TumCCA↑, TumCMig↓, TumCI↓, ROS↑, Slug↓, β-catenin/ZEB1↓, Zeb1↓, N-cadherin↓, F-actin↓, GSH↓, EMT↓, CLDN1↓, ZO-1↓,
2950- PL,    Overview of piperlongumine analogues and their therapeutic potential
- Review, Var, NA
AntiAg↑, neuroP↑, Inflam↓, NO↓, PGE2↓, MMP3↓, MMP13↓, TumCMig↓, TumCI↓, p38↑, JNK↑, NF-kB↑, ROS↑, FOXM1↓, TrxR1↓, GSH↓, Trx↓, cMyc↓, Casp3↑, Bcl-2↓, Mcl-1↓, STAT3↓, AR↓, DNAdam↑,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
2946- PL,    Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
- Review, Var, NA
ROS↑, GSH↓, DNAdam↑, ChemoSen↑, RadioS↑, BioEnh↑, selectivity↑, BioAv↓, eff↑, p‑Akt↓, mTOR↓, GSK‐3β↓, β-catenin/ZEB1↓, HK2↓, Glycolysis↓, Cyt‑c↑, Casp9↑, Casp3↑, Casp7↑, cl‑PARP↑, TrxR↓, ER Stress↑, ATF4↝, CHOP↑, Prx4↑, NF-kB↓, cycD1/CCND1↓, CDK4↓, CDK6↓, p‑RB1↓, RAS↓, cMyc↓, TumCCA↑, selectivity↑, STAT3↓, NRF2↑, HO-1↑, PTEN↑, P-gp↓, MDR1↓, MRP1↓, survivin↓, Twist↓, AP-1↓, Sp1/3/4↓, STAT1↓, STAT6↓, SOX4↑, XBP-1↑, P21↑, eff↑, Inflam↓, COX2↓, IL6↓, MMP9↓, TumMeta↓, TumCI↓, ICAM-1↓, CXCR4↓, VEGF↓, angioG↓, Half-Life↝, BioAv↑,
4965- PSO,  Cisplatin,    The synergistic antitumor effects of psoralidin and cisplatin in gastric cancer by inducing ACSL4-mediated ferroptosis
- vitro+vivo, GC, HGC27 - vitro+vivo, GC, MKN45
TumCP↓, TumCMig↓, TumCI↓, TumCG↓, *toxicity↓, eff↑, Ferroptosis↑, ACSL4↑, GPx4↓, ChemoSen↑, chemoP↑, AntiTum↑, Sepsis↓,
4699- PTS,    Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, HS587T - in-vivo, BC, MDA-MB-231
TumCMig↓, TumCI↓, E-cadherin↑, Snail↓, Slug↓, Vim↓, Zeb1↑, miR-205↑, Src↓, TumCG↓, FAK↓, EMT↓,
4689- PTS,    Pterostilbene Suppresses both Cancer Cells and Cancer Stem-Like Cells in Cervical Cancer with Superior Bioavailability to Resveratrol
eff↑, TumCCA↑, ROS↑, MMP2↓, MMP9↓, CSCs↓, CD133↓, OCT4↓, SOX2↓, Nanog↓, STAT3↓, BioAv↑, TumCI↓, ROS↑, Apoptosis↑,
1237- PTS,    Pterostilbene induces cell apoptosis and inhibits lipogenesis in SKOV3 ovarian cancer cells by activation of AMPK-induced inhibition of Akt/mTOR signaling cascade
- in-vitro, Ovarian, SKOV3
TumCMig↓, TumCI↓, MDA↑, ROS↑, BAX↑, Casp3↑, Bcl-2↓, SREBP1↓, FASN↓, AMPK↓, p‑AMPK↑, p‑P53↑, p‑TSC2↑, p‑Akt↓, p‑mTOR↓, p‑S6K↓, p‑4E-BP1↓,
1238- PTS,    Pterostilbene suppresses gastric cancer proliferation and metastasis by inhibiting oncogenic JAK2/STAT3 signaling: In vitro and in vivo therapeutic intervention
- in-vitro, GC, NA - in-vivo, NA, NA
TumCCA↑, TumCP↓, TumCMig↓, TumCI↓, TumVol↓, TumW↓, Weight∅, JAK2↓, STAT3↓,
3929- PTS,    New Insights into Dietary Pterostilbene: Sources, Metabolism, and Health Promotion Effects
- Review, Var, NA - Review, Arthritis, NA
*NRF2↑, *BioAv↑, *ROS↓, *Inflam↓, *HO-1↑, *SOD↑, *Catalase↑, *GPx↑, *lipid-P↓, *hepatoP↑, *neuroP↑, *iNOS↓, *COX2↓, TumMeta↓, SOD2↓, ROS↑, TumCI↓, TumCG↓, HDAC1↓, PTEN↑, BP↓, *GutMicro↑,
3353- QC,    Quercetin triggers cell apoptosis-associated ROS-mediated cell death and induces S and G2/M-phase cell cycle arrest in KON oral cancer cells
- in-vitro, Oral, KON - in-vitro, Nor, MRC-5
tumCV↓, selectivity↑, TumCCA↑, TumCMig↓, TumCI↓, Apoptosis↑, TumMeta↓, Bcl-2↓, BAX↑, TIMP1↑, MMP2↓, MMP9↓, *Inflam↓, *neuroP↑, *cardioP↑, p38↓, MAPK↓, Twist↓, P21↓, cycD1/CCND1↓, Casp3↑, Casp9↑, p‑Akt↓, p‑ERK↓, CD44↓, CD24↓, ChemoSen↑, MMP↓, Cyt‑c↑, AIF↑, ROS↑, Ca+2↑, Hif1a↓, VEGF↓,
3375- QC,    Quercetin Mediated TET1 Expression Through MicroRNA-17 Induced Cell Apoptosis in Melanoma Cells
- in-vitro, Melanoma, B16-BL6
TET1↑, TumCI↓,
3374- QC,    Therapeutic effects of quercetin in oral cancer therapy: a systematic review of preclinical evidence focused on oxidative damage, apoptosis and anti-metastasis
- Review, Oral, NA - Review, AD, NA
α-SMA↓, α-SMA↑, TumCP↓, tumCV↓, TumVol↓, TumCI↓, TumMeta↓, TumCMig↓, ROS↑, Apoptosis↑, BioAv↓, *neuroP↑, *antiOx↑, *Inflam↓, *Aβ↓, *cardioP↑, MMP↓, Cyt‑c↑, MMP2↓, MMP9↓, EMT↓, MMPs↓, Twist↓, Slug↓, Ca+2↑, AIF↑, Endon↑, P-gp↓, LDH↑, HK2↓, PKA↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, GRP78/BiP↑, Casp12↑, CHOP↑,
3373- QC,    The Effect of Quercetin in the Yishen Tongluo Jiedu Recipe on the Development of Prostate Cancer through the Akt1-related CXCL12/ CXCR4 Pathway
- in-vitro, Pca, DU145
TumCP↓, Casp3↑, Bcl-2↓, Apoptosis↑, TumCI↓, TumCMig↓, CXCL12↓, CXCR4↓,
2340- QC,    Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2)
- in-vitro, OS, NA
TumCG↓, GlucoseCon↓, TumCI↓, GLUT1↓, PKM2↓, LDHA↓, Glycolysis↓, lactateProd↓, HK2↓, eff↑,
877- RES,    Resveratrol Inhibits Invasion and Metastasis of Colorectal Cancer Cells via MALAT1 Mediated Wnt/β-Catenin Signal Pathway
- in-vitro, CRC, LoVo - in-vitro, CRC, HCT116
MALAT1↓, Wnt/(β-catenin)↓, TumCI↓, TumMeta↓,
2332- RES,    Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism
- Review, Var, NA
Glycolysis↓, GLUT1↓, PFK1↓, Hif1a↓, ROS↑, PDH↑, AMPK↑, TumCG↓, TumCI↓, TumCP↓, p‑NF-kB↓, SIRT1↑, SIRT3↑, LDH↓, PI3K↓, mTOR↓, PKM2↓, R5P↝, G6PD↓, TKT↝, talin↓, HK2↓, GRP78/BiP↑, GlucoseCon↓, ER Stress↑, Warburg↓, PFK↓,
2441- RES,    Anti-Cancer Properties of Resveratrol: A Focus on Its Impact on Mitochondrial Functions
- Review, Var, NA
*toxicity↓, *BioAv↝, *Dose↝, *hepatoP↑, *neuroP↑, *AntiAg↑, *COX2↓, *antiOx↑, *ROS↓, *ROS↑, PI3K↓, Akt↓, NF-kB↓, Wnt↓, β-catenin/ZEB1↓, NRF2↑, GPx↑, HO-1↑, BioEnh?, PTEN↑, ChemoSen↑, eff↑, mt-ROS↑, Warburg↓, Glycolysis↓, GlucoseCon↓, GLUT1↓, lactateProd↓, HK2↓, EGFR↓, cMyc↓, ROS↝, MMPs↓, MMP7↓, survivin↓, TumCP↓, TumCMig↓, TumCI↓,
3070- RES,    Resveratrol inhibits tumor progression by down-regulation of NLRP3 in renal cell carcinoma
- in-vitro, RCC, ACHN - in-vitro, RCC, 786-O - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, NLRP3↓,
3082- RES,    Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation
- in-vitro, PC, PANC1 - in-vitro, PC, MIA PaCa-2 - in-vivo, NA, NA
VEGF↓, CXCL12↓, IL6↓, α-SMA↓, Hif1a↓, TumCI↓, EMT↓,
2988- RES,    The Antimetastatic Effects of Resveratrol on Hepatocellular Carcinoma through the Downregulation of a Metastasis-Associated Protease by SP-1 Modulation
- in-vitro, HCC, HUH7
TumCMig↓, TumCI↓, uPA↓, Sp1/3/4↓,
3095- RES,    Resveratrol suppresses migration, invasion and stemness of human breast cancer cells by interfering with tumor-stromal cross-talk
- in-vitro, BC, NA
TumCP↓, TumCMig↓, TumCI↓, cycD1/CCND1↓, cMyc↓, MMP2↓, MMP9↓, SOX2↓, Akt↓, STAT3↓, α-SMA↓,
3092- RES,    Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action
- Review, BC, MDA-MB-231 - Review, BC, MCF-7
TumCP↓, tumCV↓, TumCI↓, TumMeta↓, *antiOx↑, *cardioP↑, *Inflam↓, *neuroP↑, *Keap1↓, *NRF2↑, *ROS↓, p62↓, IL1β↓, CRP↓, VEGF↓, Bcl-2↓, MMP2↓, MMP9↓, FOXO4↓, POLD1↓, CK2↓, MMP↓, ROS↑, Apoptosis↑, TumCCA↑, Beclin-1↓, Ki-67↓, ATP↓, GlutMet↓, PFK↓, TGF-β↓, SMAD2↓, SMAD3↓, Vim?, Snail↓, Slug↓, E-cadherin↑, EMT↓, Zeb1↓, Fibronectin↓, IGF-1↓, PI3K↓, Akt↓, HO-1↑, eff↑, PD-1↓, CD8+↑, Th1 response↑, CSCs↓, RadioS↑, SIRT1↑, Hif1a↓, mTOR↓,
3089- RES,    The Role of Resveratrol in Cancer Therapy
- Review, Var, NA
angioG↓, VEGF↓, EGFR↓, FGF↑, TumCMig↓, TumCI↓, TIMP1↑, MMP2↓, MMP9↓, NF-kB↓, Hif1a↓, PI3K↓, Akt↓, MAPK↓, EMT↓, AR↓,
3086- RES,    Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3 - in-vitro, Pca, DU145
TET1↑, TumCMig↓, TumCI↓, TIMP2↑, TIMP3↑, MMP2↓, MMP9↓,
3083- RES,    Resveratrol suppresses breast cancer cell invasion by inactivating a RhoA/YAP signaling axis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
YAP/TEAD↓, Rho↓, FAK↓, MMP9↓, ChemoSen↑, RAS↓, ROCK1↓, TumCI↓, TumMeta↓,
1048- RosA,  Ger,    Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis
- in-vivo, Colon, MC38
TumCMig↓, TumCI↓, PD-1↓, COX2↓, PD-L1↓,
3027- RosA,    Rosmarinic acid inhibits proliferation and invasion of hepatocellular carcinoma cells SMMC 7721 via PI3K/AKT/mTOR signal pathway
- in-vitro, HCC, SMMC-7721 cell
TumCP↓, TumCCA↑, Apoptosis↑, EMT↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, TumCMig↓, MMPs↓, Vim↓,
3010- RosA,    Exploring the mechanism of rosmarinic acid in the treatment of lung adenocarcinoma based on bioinformatics methods and experimental validation
- in-vitro, Lung, A549 - in-vivo, NA, NA
TumCG↓, Ki-67↓, FABP4↑, PPARα↑, ROS↑, Apoptosis↑, MMP9↓, IGFBP3↓, MMP2↓, EMT↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, Gli1↓, PPARγ↑, Cyt‑c↑,
3035- RosA,    Rosmarinic Acid Decreases the Malignancy of Pancreatic Cancer Through Inhibiting Gli1 Signaling
- in-vitro, PC, NA - in-vivo, NA, NA
Gli1↓, TumCCA↑, TumCMig↓, TumCI↓, CDK2↓, cycE/CCNE↓, P21↑, p27↑,
4900- Sal,    Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications
- Review, BC, NA
CSCs↓, Apoptosis↑, TumAuto↑, necrosis↑, TumCP↓, TumCI↓, TumCMig↓, TumCG↓, TumMeta↓, eff↑, Bcl-2↓, cMyc↓, Snail↓, ALDH↓, Myc↓, AR↓, ROS↑, NF-kB↓, PTCH1↓, Smo↓, Gli1↓, GLI2↓, Wnt↓, mTOR↓, GSK‐3β↓, cycD1/CCND1↓, survivin↓, P21↑, p27↑, CHOP↑, Ca+2↑, DNAdam↑, Hif1a↓, VEGF↓, angioG↓, MMP↓, ATP↓, p‑P53↑, γH2AX↑, ChemoSen↑,
4742- Se,    Antitumor Effects of Selenium
- Review, Var, NA - Review, Arthritis, NA - Review, Sepsis, NA
*antiOx↓, *Inflam↓, Risk↓, TumCI↓, TumMeta↓, radioP↑, chemoP↑, Apoptosis↑, ROS↑, DNAdam↑, Dose↑, selectivity↑, *other↓, *BioAv↑, ROS↑, MMP↓, Casp↑, *Imm↑, *Pain↓, Sepsis↓, MMP2↓, MMP9↓, *Half-Life↓,
3188- SFN,    Sulforaphane inhibited tumor necrosis factor-α induced migration and invasion in estrogen receptor negative human breast cancer cells
- in-vitro, BC, NA
TNF-α↓, TumCI↓, TumMeta↓, MMPs↓, MMP2↓, MMP9↓, MMP13↓,
2448- SFN,    Sulforaphane and bladder cancer: a potential novel antitumor compound
- Review, Bladder, NA
Apoptosis↑, TumCG↓, TumCI↓, TumMeta↓, glucoNG↓, ChemoSen↑, TumCCA↑, Casp3↑, Casp7↑, cl‑PARP↑, survivin↓, EGFR↓, HER2/EBBR2↓, ATP↓, Glycolysis↓, mt-OXPHOS↓, AKT1↓, HK2↓, Hif1a↓, ROS↑, NRF2↑, EMT↓, COX2↓, MMP2↓, MMP9↓, Zeb1↓, Snail↓, HDAC↓, HATs↓, MMP↓, Cyt‑c↓, Shh↓, Smo↓, Gli1↓, BioAv↝, BioAv↝, Dose↝,
1452- SFN,    Sulforaphane Suppresses the Nicotine-Induced Expression of the Matrix Metalloproteinase-9 via Inhibiting ROS-Mediated AP-1 and NF-κB Signaling in Human Gastric Cancer Cells
- in-vitro, GC, AGS
MMP9↓, p38↓, ERK↓, AP-1↓, ROS↓, NF-kB↓, TumCI↓, MMP9↓, HDAC↓, Glycolysis↓, Hif1a↓, *memory↑, *cognitive↑,
1434- SFN,  GEM,    Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity
- in-vitro, CCA, HuCCT1 - in-vitro, CCA, HuH28 - in-vivo, NA, NA
HDAC↓, ac‑H3↑, ChemoSen↑, tumCV↓, TumCP↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, TumCI↓, VEGF↓, VEGFR2↓, Hif1a↓, eNOS↓, EMT?, TumCG↓, Ki-67↓, TUNEL↑, P21↑, p‑Chk2↑, CDC25↓, BAX↑, *ROS↓, NQO1?,
1499- SFN,    Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway
- in-vitro, BC, NA
TumCMig↓, TumCI↓, FAK↓, p‑MEK↓, p‑ERK↓,
1457- SFN,    Sulforaphane Inhibits IL-1β-Induced IL-6 by Suppressing ROS Production, AP-1, and STAT3 in Colorectal Cancer HT-29 Cells
- in-vitro, CRC, HT-29
IL6↓, ROS↓, TumCP↓, TumCI↓, p38↓, AP-1↓,
1462- SFN,    Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells
- in-vitro, Bladder, T24
EMT↓, TumCI↓, TumCMig↓, E-cadherin↑, Zeb1↓, Snail↓, COX2↝, MMP2↝, MMP9↝,
1466- SFN,    Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway
- vitro+vivo, Thyroid, FTC-133
TumCP↓, TumCCA↑, Apoptosis↑, TumCMig↓, TumCI↓, EMT↓, Slug↓, Twist↓, MMP2↓, MMP9↓, TumCG↓, p‑Akt↓, P21↑, ERK↑, p38↑, ROS↑, *toxicity∅, MMP↓, eff↓,
2166- SFN,    Sulforaphane targets cancer stemness and tumor initiating properties in oral squamous cell carcinomas via miR-200c induction
- in-vitro, Oral, NA - in-vivo, NA, NA
CSCs↓, selectivity↑, TumCMig↓, TumCI↓,
3306- SIL,  Rad,    Radioprotective and radiosensitizing properties of silymarin/silibinin in response to ionizing radiation
- Review, Var, NA
radioP↑, RadioS↑, TumCMig↓, TumCI↓, angioG↓, Apoptosis↑, DNAdam↓, ROS↑, *ROS↓, *Inflam↓,
3296- SIL,    Silibinin induces oral cancer cell apoptosis and reactive oxygen species generation by activating the JNK/c-Jun pathway
- in-vitro, Oral, Ca9-22 - in-vivo, Oral, YD10B
TumCP↓, TumCCA↑, ROS↑, SOD1↓, SOD2↓, *JNK↑, toxicity?, TumCMig↓, TumCI↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, P53↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Bcl-2↓, SOD↓,
3326- SIL,    Silymarin suppresses proliferation of human hepatocellular carcinoma cells under hypoxia through downregulation of the HIF-1α/VEGF pathway
- in-vitro, Liver, HepG2 - in-vitro, Liver, Hep3B
*hepatoP↑, chemoPv↑, ChemoSen↑, TumCP↓, TumCMig↓, TumCI↓, Hif1a↓, VEGF↓, angioG↓,
1127- SIL,    Silibinin suppresses epithelial–mesenchymal transition in human non-small cell lung cancer cells by restraining RHBDD1
- in-vitro, Lung, A549
TumCP↓, TumCMig↓, TumCI↓, EMT↓, RHBDD1↓,
2360- SK,    Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway
- in-vitro, NPC, HONE1 - in-vitro, NPC, SUNE-1
TumCP↓, Apoptosis↑, TumCMig↓, TumCI↓, GlucoseCon↓, lactateProd↓, ATP↓, PKM2↓, PI3K↓, Akt↓, MMP3↓, MMP9↓, TIMP1↑,
2232- SK,    Shikonin Induces Autophagy and Apoptosis in Esophageal Cancer EC9706 Cells by Regulating the AMPK/mTOR/ULK Axis
- in-vitro, ESCC, EC9706
tumCV↓, TumCMig↓, TumCI↓, TumAuto↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑PARP↑, AMPK↑, mTOR↑, TumVol↓, OS↑, LC3I↑,
2234- SK,    Shikonin Suppresses Cell Tumorigenesis in Gastric Cancer Associated with the Inhibition of c-Myc and Yap-1
- in-vitro, GC, NA
TumCP↓, TumCI↓, TumCMig↓, cMyc↓, YAP/TEAD↓,
2417- SK,    Shikonin inhibits the Warburg effect, cell proliferation, invasion and migration by downregulating PFKFB2 expression in lung cancer
- in-vitro, Lung, A549 - in-vitro, Lung, H446
TumCP↓, TumCMig↓, TumCI↓, GlucoseCon↓, lactateProd↓, PFKFB2↓, Warburg↓, GLUT1∅, LDHA∅, PKM2∅, GLUT3∅, PDH∅,
3041- SK,    Promising Nanomedicines of Shikonin for Cancer Therapy
- Review, Var, NA
Glycolysis↓, TAMS↝, BioAv↓, Half-Life↝, P21↑, ERK↓, ROS↑, GSH↓, MMP↓, TrxR↓, MMP13↓, MMP2↓, MMP9↓, SIRT2↑, Hif1a↓, PKM2↓, TumCP↓, TumMeta↓, TumCI↓,
3046- SK,    Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin β1 expression and the ERK1/2 signaling pathway
- in-vitro, Lung, A549
TumCP↓, TumCI↓, TumCMig↓, p‑ERK↓, ITGB1↓,
3048- SK,    Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, 4T1 - in-vitro, Nor, MCF12A - in-vivo, NA, NA
tumCV↓, selectivity↑, EMT↓, TumCMig↓, TumCI↓, E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, β-catenin/ZEB1↓, GSK‐3β↑,
2190- SK,    Shikonin exerts antitumor activity by causing mitochondrial dysfunction in hepatocellular carcinoma through PKM2-AMPK-PGC1α signaling pathway
- in-vitro, HCC, HCCLM3
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, MMP↓, ROS↑, OCR↓, ATP↓, PKM2↓,
2183- SK,    Shikonin Inhibites Migration and Invasion of Thyroid Cancer Cells by Downregulating DNMT1
- in-vitro, Thyroid, TPC-1
TumCMig↓, TumCI↓, PTEN↑, DNMT1↓,
2182- SK,  Cisplatin,    Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway
- in-vitro, Lung, A549 - in-vitro, Lung, PC9 - in-vivo, NA, NA
tumCV↓, TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, PKM2↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, ChemoSen↑, TumVol↓, TumW↓, GLUT1↓,
2210- SK,    Shikonin inhibits the cell viability, adhesion, invasion and migration of the human gastric cancer cell line MGC-803 via the Toll-like receptor 2/nuclear factor-kappa B pathway
- in-vitro, BC, MGC803
TumCA↓, TumCI↓, TumCMig↓, MMP2↓, MMP7↓, TLR2↓, p65↓, NF-kB↓, eff↑, ROS↑,
2203- SK,    Shikonin suppresses small cell lung cancer growth via inducing ATF3-mediated ferroptosis to promote ROS accumulation
- in-vitro, Lung, NA
TumCP↓, Apoptosis↓, TumCMig↓, TumCI↓, Ferroptosis↑, ERK↓, GPx4↓, 4-HNE↑, ROS↑, GSH↓, ATF3↑, HDAC1↓, ac‑Histones↑,
1191- SM,    Salvia miltiorrhiza extract inhibits TPA‑induced MMP‑9 expression and invasion through the MAPK/AP‑1 signaling pathw
- in-vitro, BC, MCF-7
Inflam↓, MMP9↓, TumCI↓, AP-1↓, lipidLev↓,
359- SNP,    Anti-cancer & anti-metastasis properties of bioorganic-capped silver nanoparticles fabricated from Juniperus chinensis extract against lung cancer cells
- in-vitro, Lung, A549 - in-vitro, Nor, HEK293
Casp3↑, Casp9↑, P53↑, ROS↑, MMP2↓, MMP9↓, TumCCA↑, *toxicity↓, TumCMig↓, TumCI↓,
4426- SNP,    Antiangiogenic properties of silver nanoparticles
- Study, NA, NA
angioG↑, TumCG↓, TumCI↓, TumMeta↓, VEGF↓, PI3K↓, Akt↓,
962- TQ,    Thymoquinone affects hypoxia-inducible factor-1α expression in pancreatic cancer cells via HSP90 and PI3K/AKT/mTOR pathways
- in-vitro, PC, PANC1 - in-vitro, Nor, hTERT-HPNE - in-vitro, PC, AsPC-1 - in-vitro, PC, Bxpc-3
TumCMig↓, TumCI↓, Apoptosis↑, Hif1a↓, PI3k/Akt/mTOR↓, TumCCA↑, *toxicity↓, *TumCI∅, *TumCMig∅,
3559- TQ,    Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer’s disease
- Review, AD, NA - Review, Var, NA
*antiOx↑, *Inflam↓, *AChE↓, AntiCan↑, *cardioP↑, *RenoP↑, *neuroP↑, *hepatoP↑, TumCG↓, Apoptosis↑, PI3K↓, Akt↑, TumCCA↑, angioG↓, *NF-kB↓, *TLR2↓, *TLR4↓, *MyD88↓, *TRIF↓, *IRF3↓, *IL1β↓, *IL6↓, *IL12↓, *NRF2↑, *COX2↓, *VEGF↓, *MMP9↓, *cMyc↓, *cycD1/CCND1↓, *TumCP↓, *TumCI↓, *MDA↓, *TGF-β↓, *CRP↓, *Casp3↓, *GSH↑, *IL10↑, *iNOS↑, *lipid-P↓, *SOD↑, *H2O2↓, *ROS↓, *LDH↓, *Catalase↑, *GPx↑, *AChE↓, *cognitive↑, *MAPK↑, *JNK↑, *BAX↓, *memory↑, *Aβ↓, *MMP↑,
3425- TQ,    Advances in research on the relationship between thymoquinone and pancreatic cancer
Apoptosis↑, TumCP↓, TumCI↓, TumMeta↓, ChemoSen↑, angioG↓, Inflam↓, NF-kB↓, PI3K↓, Akt↓, TGF-β↓, Jun↓, p38↑, MAPK↑, MMP9↓, PKM2↓, ROS↑, JNK↑, MUC4↓, TGF-β↑, Dose↝, FAK↓, NOTCH↓, PTEN↑, mTOR↓, Warburg↓, XIAP↓, COX2↓, Casp9↑, Ki-67↓, CD34↓, VEGF↓, MCP1↓, survivin↓, Cyt‑c↑, Casp3↑, H4↑, HDAC↓,
3403- TQ,    A multiple endpoint approach reveals potential in vitro anticancer properties of thymoquinone in human renal carcinoma cells
- in-vitro, RCC, 786-O
tumCV↓, ROS↑, TumCCA↑, eff↓, TumCI↓,
3411- TQ,    Anticancer and Anti-Metastatic Role of Thymoquinone: Regulation of Oncogenic Signaling Cascades by Thymoquinone
- Review, Var, NA
p‑STAT3↓, cycD1/CCND1↓, JAK2↓, β-catenin/ZEB1↓, cMyc↓, MMP7↓, MET↓, p‑Akt↓, p‑mTOR↓, CXCR4↓, Bcl-2↓, BAX↑, ROS↑, Cyt‑c↑, Twist↓, Zeb1↓, E-cadherin↑, p‑p38↑, p‑MAPK↑, ERK↑, eff↑, ERK↓, TumCP↓, TumCMig↓, TumCI↓,
2127- TQ,    Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways
- Review, GBM, NA
chemoP↑, ChemoSen↑, BioAv↑, PTEN↑, PI3K↓, Akt↓, TumCCA↓, NF-kB↓, p‑Akt↓, p65↓, XIAP↓, Bcl-2↓, COX2↓, VEGF↓, mTOR↓, RAS↓, Raf↓, MEK↓, ERK↓, MMP2↓, MMP9↓, TumCMig↓, TumCI↓, Casp↑, cl‑PARP↑, ROS⇅, ROS↑, MMP↓, eff↑, Telomerase↓, DNAdam↑, Apoptosis↑, STAT3↓, RadioS↑,
1929- TQ,    Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells
- in-vitro, Bladder, 5637 - in-vitro, Bladder, T24
tumCV↓, TumCP↓, TumCI↓, Casp↑, ROS↑, PD-L1↓, EMT↓, MMP↓, eff↓,
1930- TQ,    Therapeutic implications and clinical manifestations of thymoquinone
- Review, Var, NA
AntiCan↑, antiOx↑, Inflam↓, TumCP↓, TumCCA↑, Apoptosis↑, ROS↑, TumMeta↓, TumCI↓,
4565- TQ,    Thymoquinone in the clinical treatment of cancer: Fact or fiction?
- Review, BC, NA
Dose↝, TumCCA↑, P21↑, cycD1/CCND1↓, TumCI↑, TumMeta↓, Bcl-2↓, Bcl-xL↓, survivin↓, PTEN↑, Akt↓, P53↑, NF-kB↓, cardioP↑, Dose↝,
5019- UA,    Ursolic acid in colorectal cancer: mechanisms, current status, challenges, and future research directions
- Review, Var, NA
TumCP↓, Diff↑, Apoptosis↑, TumCI↓, angioG↓,
4856- Uro,    Study on the biological mechanism of urolithin a on nasopharyngeal carcinoma in vitro
- in-vitro, NPC, CNE1 - in-vitro, NPC, CNE2
Apoptosis↑, MMP↓, ROS↑, E-cadherin↑, BAX↑, cl‑Casp3↑, PARP↑, MMP2↓, MMP9↓, N-cadherin↓, Vim↓, Snail↓, eff↓, TumCP↓, TumCMig↓, TumCI↓, EMT↓,
4851- Uro,    Urolithin A suppressed osteosarcoma cell migration and invasion via targeting MMPs and AKT1
- in-vitro, OS, MG63
TumCMig↓, TumCI↓, TumCA↑, MMP2?, MMP9?,
4849- Uro,    Urolithin A suppresses tumor progression and induces autophagy in gastric cancer via the PI3K/Akt/mTOR pathway
- vitro+vivo, GC, NA
TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, TumAuto↑, TumCG↓, chemoP↑, ChemoSen↑,
4844- Uro,    Urolithin A Inhibits Epithelial–Mesenchymal Transition in Lung Cancer Cells via P53-Mdm2-Snail Pathway
- in-vitro, Lung, A549 - in-vitro, Lung, H460
TumCMig↓, TumCI↓, EMT↓, Snail↓, MDM2↑, P53↑, E-cadherin↑, N-cadherin↓, Vim↓,
3143- VitC,  ATO,    Vitamin C enhances the sensitivity of osteosarcoma to arsenic trioxide via inhibiting aerobic glycolysis
- in-vitro, OS, NA
TumCP↓, TumCMig↓, TumCI↓, eff↑, Glycolysis↓, lactateProd↓, ATP↓, PGK1↓, PGM1↓, LDHA↓,
3130- VitC,    Effect of high-dose vitamin C on MMP2 expression and invasive ability in human pancreatic cancer cell line PANC-1
- in-vitro, PC, PANC1
MMP2↓, TumCI↓,
1817- VitK2,    Research progress on the anticancer effects of vitamin K2
- Review, Var, NA
TumCCA↑, Apoptosis↑, TumAuto↑, TumCI↓, TumCG↓, ChemoSen↓, ChemoSideEff↓, toxicity∅, eff↑, cycD1/CCND1↓, CDK4↓, eff↑, IKKα↓, NF-kB↓, other↑, p27↑, cMyc↓, i-ROS↑, Bcl-2↓, BAX↑, p38↑, MMP↓, Casp9↑, p‑ERK↓, RAS↓, MAPK↓, p‑P53↑, Casp8↑, Casp3↑, cJun↑, MMPs↓, eff↑, eff↑,
1820- VitK3,    Vitamin K3 (menadione) suppresses epithelial-mesenchymal-transition and Wnt signaling pathway in human colorectal cancer cells
- in-vitro, CRC, SW480 - in-vitro, CRC, SW-620
selectivity↑, TumCI↓, TumCMig↓, EMT↓, E-cadherin↑, ZO-1↑, N-cadherin↓, Vim↓, Zeb1↓, MMP2↓, MMP9↓, TOPflash↓, β-catenin/ZEB1↓, p300↓, cycD1/CCND1↓, TumCCA↑,
1755- WBV,    Reduction of breast cancer extravasation via vibration activated osteocyte regulation
Dose∅, TumMeta↑, eff∅, Piezo1↑, COX2↑, RANKL↓, TumCG∅, tumCV∅, TumCI↓,
1761- WBV,    Low Intensity Vibration Mitigates Tumor Progression and Protect Bone Quantity and Quality in a Murine Model of Myeloma
- in-vivo, Melanoma, NA
Dose∅, BMD↑, TumCI↓,
1751- WBV,    Yoda1 Enhanced Low-Magnitude High-Frequency Vibration on Osteocytes in Regulation of MDA-MB-231 Breast Cancer Cell Migration
- in-vitro, BC, MDA-MB-231 - in-vitro, AML, RAW264.7
BMD↑, YAP/TEAD↑, TumCG↓, Strength↑, TumCI↓, Fas↑, Ca+2↑,
1222- Z,    Zinc regulates primary ovarian tumor growth and metastasis through the epithelial to mesenchymal transition
- in-vitro, Ovarian, NA
EMT↑, TumCMig↑, TumCI↑, ERK↑, Akt↑,
961- Z,    Zinc Downregulates HIF-1α and Inhibits Its Activity in Tumor Cells In Vitro and In Vivo
- in-vitro, RCC, RCC4 - vitro+vivo, GBM, U373MG - in-vitro, Nor, HUVECs
Hif1a↓, HIF-1↓, VEGF↓, TumCI↓,
2414- β‐Ele,    Beta‐elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vivo, NA, NA
TumCMig↓, TumCI↓, TumMeta↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PKM2↓, EGFR↓, GLUT1↓, LDHA↓, ECAR↓, OCR↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 240

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

chemoPv↑, 6,  

Redox & Oxidative Stress ⓘ

4-HNE↑, 1,   antiOx↑, 2,   ATF3↑, 1,   Copper↑, 1,   CYP1A1↑, 1,   CYP2E1↑, 1,   Fenton↑, 1,   Ferroptosis↑, 8,   GPx↑, 1,   GPx4↓, 4,   GSH↓, 14,   GSH↑, 1,   GSTs↑, 1,   H2O2↑, 1,   HO-1↓, 3,   HO-1↑, 6,   Iron↑, 1,   Keap1↓, 1,   Keap1↑, 1,   lipid-P?, 1,   lipid-P↓, 2,   lipid-P↑, 2,   MAD↓, 1,   MDA↑, 5,   NQO1?, 1,   NQO1↑, 1,   NRF2↓, 7,   NRF2↑, 8,   OXPHOS↑, 1,   mt-OXPHOS↓, 1,   PARK2↑, 1,   Prx4↑, 1,   PYCR1↓, 1,   ROS↓, 7,   ROS↑, 70,   ROS⇅, 2,   ROS↝, 1,   ROS∅, 1,   i-ROS↓, 1,   i-ROS↑, 1,   mt-ROS↑, 3,   SIRT3↑, 2,   SOD↓, 3,   SOD↑, 1,   SOD1↓, 1,   SOD1↑, 1,   SOD2↓, 2,   SOD2↑, 1,   TKT↝, 1,   Trx↓, 1,   TrxR↓, 3,   TrxR1↓, 1,  

Metal & Cofactor Biology ⓘ

Ferritin↓, 1,   Tf↓, 1,   Tf↑, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 2,   ATP↓, 7,   BCR-ABL↓, 1,   CDC2↓, 2,   CDC25↓, 5,   EGF↓, 1,   FGFR1↓, 1,   MEK↓, 2,   p‑MEK↓, 2,   MMP↓, 29,   MMP↑, 1,   Mortalin↓, 1,   MPT↑, 1,   mtDam↑, 2,   OCR↓, 5,   PINK1↑, 1,   Raf↓, 1,   c-Raf↓, 1,   XIAP↓, 8,  

Core Metabolism/Glycolysis ⓘ

12LOX↓, 1,   ACC↓, 2,   ACSL4↑, 1,   AKT1↓, 2,   AMPK↓, 1,   AMPK↑, 13,   AMPK↝, 1,   p‑AMPK↑, 5,   ATG7↑, 1,   CAIX↓, 1,   cMyc↓, 15,   CYP3A4↓, 1,   ECAR↓, 2,   FABP4↑, 1,   FASN↓, 5,   FDG↓, 1,   G6PD↓, 2,   glucoNG↓, 1,   GlucoseCon↓, 9,   GlutMet↓, 1,   Glycolysis↓, 20,   ac‑Histones↑, 1,   HK2↓, 11,   IDH1↑, 1,   lactateProd↓, 9,   LDH↓, 5,   LDH↑, 1,   LDHA↓, 8,   LDHA∅, 1,   LDL↓, 1,   lipidLev↓, 1,   lipoGen↓, 1,   NADPH↓, 1,   PDH↑, 2,   PDH↝, 1,   PDH∅, 1,   PDHB↓, 1,   PDK1↓, 2,   p‑PDK1↓, 1,   PFK↓, 4,   PFK1↓, 1,   PFKFB2↓, 1,   PGK1↓, 1,   PGM1↓, 1,   PI3K/Akt↓, 2,   PI3k/Akt/mTOR↓, 1,   PIK3CA↓, 1,   PKM2↓, 17,   PKM2∅, 1,   POLD1↓, 1,   PPARα↓, 1,   PPARα↑, 1,   PPARα↝, 1,   PPARγ↑, 2,   R5P↝, 1,   RARα↓, 1,   RARβ↑, 1,   RARγ↑, 1,   p‑S6↓, 1,   p‑S6K↓, 1,   SIRT1↓, 1,   SIRT1↑, 4,   SIRT2↑, 1,   SREBP1↓, 1,   Warburg↓, 4,  

Cell Death ⓘ

Akt↓, 48,   Akt↑, 2,   p‑Akt↓, 18,   APAF1↑, 1,   Apoptosis↓, 2,   Apoptosis↑, 89,   Bak↑, 1,   BAX↑, 32,   Bax:Bcl2↑, 5,   Bcl-2↓, 37,   Bcl-xL↓, 8,   BIM↑, 1,   BMP2↓, 1,   Casp↑, 8,   Casp1↓, 1,   cl‑Casp1↑, 1,   proCasp1↓, 1,   Casp10∅, 1,   Casp12↑, 1,   Casp2↑, 1,   Casp3↓, 2,   Casp3↑, 30,   cl‑Casp3↑, 11,   Casp7↑, 4,   cl‑Casp7↑, 1,   Casp8↑, 10,   Casp8∅, 1,   cl‑Casp8↑, 2,   Casp9↑, 19,   cl‑Casp9↑, 3,   CBP↓, 1,   cFLIP↓, 1,   p‑Chk2↑, 1,   CK2↓, 3,   Cyt‑c↓, 1,   Cyt‑c↑, 26,   DR4↑, 3,   DR4∅, 1,   DR5↑, 4,   DR5∅, 1,   Endon↑, 1,   FADD∅, 1,   Fas↑, 5,   FasL↑, 1,   Ferroptosis↑, 8,   GSDMD↑, 1,   IAP1↓, 1,   cl‑IAP2↑, 1,   iNOS↓, 1,   JNK↑, 6,   p‑JNK↓, 1,   MAPK↓, 12,   MAPK↑, 3,   p‑MAPK↑, 1,   Mcl-1↓, 3,   Mcl-1↑, 1,   MDM2↓, 2,   MDM2↑, 1,   miR-7641↓, 1,   Myc↓, 1,   Myc↑, 1,   Necroptosis↑, 1,   necrosis↑, 2,   p27↓, 1,   p27↑, 5,   P2X7↓, 1,   p38↓, 5,   p38↑, 4,   p‑p38↓, 1,   p‑p38↑, 1,   Pyro↑, 1,   survivin↓, 17,   Telomerase↓, 4,   TRAILR↑, 1,   TumCD↑, 2,   TUNEL↑, 1,   YAP/TEAD↓, 2,   YAP/TEAD↑, 1,   β-TRCP↑, 1,  

Kinase & Signal Transduction ⓘ

cSrc↓, 1,   EF-1α↓, 1,   HER2/EBBR2↓, 6,   p‑HER2/EBBR2↓, 1,   Sp1/3/4↓, 11,   TSC2↑, 1,   p‑TSC2↑, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 1,   cJun↑, 2,   H3↑, 1,   ac‑H3↑, 2,   H4↑, 2,   ac‑H4↑, 1,   HATs↓, 3,   HATs↑, 1,   miR-145↑, 1,   miR-192-5p↑, 1,   miR-205↑, 1,   miR-21↓, 2,   miR-30a-5p↑, 1,   other↓, 1,   other↑, 1,   other↝, 1,   p‑pRB↓, 1,   TLE1↓, 1,   tumCV↓, 28,   tumCV∅, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 11,   cl‑CHOP↑, 1,   eIF2α↑, 1,   p‑eIF2α↑, 2,   ER Stress↑, 11,   GRP78/BiP↓, 1,   GRP78/BiP↑, 7,   HSP70/HSPA5↓, 2,   e-HSP70/HSPA5↓, 1,   HSP90↓, 4,   HSPs↓, 1,   IRE1↑, 2,   PERK↑, 3,   p‑PERK↑, 1,   XBP-1↑, 1,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   Beclin-1↓, 1,   LC3A↑, 1,   LC3I↑, 1,   LC3II↑, 5,   p62↓, 3,   p62↑, 1,   p‑p62↑, 1,   TumAuto↑, 13,  

DNA Damage & Repair ⓘ

ATM↑, 1,   DNAdam↓, 1,   DNAdam↑, 13,   DNMT1↓, 3,   DNMT1↑, 1,   m-FAM72A↓, 1,   p16↑, 1,   P53?, 1,   P53↓, 1,   P53↑, 19,   p‑P53↑, 3,   p73↑, 1,   PARP↓, 1,   PARP↑, 1,   cl‑PARP↑, 19,   PCLAF↓, 1,   PCNA↓, 5,   TP53↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 4,   CDK1↑, 1,   CDK2↓, 11,   CDK2↑, 2,   CDK4↓, 12,   CDK4↑, 1,   CDK4∅, 1,   Cyc↓, 1,   cycA1/CCNA1↓, 2,   CycB/CCNB1↓, 4,   cycD1/CCND1↓, 25,   cycD1/CCND1∅, 1,   CycD3↓, 1,   cycE/CCNE↓, 7,   P21?, 1,   P21↓, 1,   P21↑, 19,   RB1↓, 1,   RB1↑, 1,   p‑RB1↓, 3,   TumCCA↓, 2,   TumCCA↑, 59,  

Proliferation, Differentiation & Cell State ⓘ

p‑4E-BP1↓, 1,   ALDH↓, 1,   BMI1↓, 1,   CD133↓, 9,   CD24↓, 3,   CD34↓, 1,   CD44↓, 6,   cFos↓, 2,   CIP2A↓, 1,   cMET↓, 1,   p‑cMET↑, 1,   cMYB↓, 1,   CSCs↓, 18,   Diff↑, 3,   EMT?, 1,   EMT↓, 63,   EMT↑, 2,   ERK↓, 20,   ERK↑, 6,   ERK↝, 1,   p‑ERK↓, 7,   FGF↓, 1,   FGF↑, 1,   FOXM1↓, 1,   FOXO↑, 1,   FOXO3↑, 1,   p‑FOXO3↓, 1,   FOXO4↓, 1,   Gli1↓, 5,   GSK‐3β↓, 4,   GSK‐3β↑, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 8,   HDAC1↓, 2,   HDAC4↓, 1,   HDAC6↓, 2,   HDAC8↓, 1,   HH↓, 1,   IGF-1↓, 2,   IGF-1R↓, 1,   IGFBP3↓, 1,   IGFBP3↑, 2,   p‑IGFR↓, 1,   Jun↓, 1,   Let-7↑, 1,   LRP6↓, 2,   p‑LRP6↓, 2,   MCM2↓, 1,   miR-194↑, 1,   miR-34a↑, 2,   miR-99↑, 1,   mTOR↓, 31,   mTOR↑, 3,   mTOR↝, 1,   p‑mTOR↓, 8,   mTORC1↓, 3,   mTORC2↓, 1,   mTORC2↑, 1,   Nanog↓, 5,   Nestin↓, 3,   NOTCH↓, 4,   NOTCH1↓, 1,   NOTCH1↝, 1,   NOTCH3↓, 1,   OCT4↓, 6,   p300↓, 2,   p‑P70S6K↓, 1,   P90RSK↓, 1,   p‑P90RSK↑, 1,   PI3K↓, 33,   p‑PI3K↓, 5,   Piezo1↑, 1,   PTCH1↓, 1,   PTEN↑, 12,   RAS↓, 6,   RAS↑, 1,   SCF↓, 1,   Shh↓, 2,   Smo↓, 3,   SOX2↓, 6,   Src↓, 2,   STAT↓, 3,   STAT1↓, 1,   p‑STAT1↓, 1,   p‑STAT2↓, 1,   STAT3↓, 24,   STAT3↑, 1,   p‑STAT3↓, 5,   STAT6↓, 2,   TCF-4↓, 1,   TOP1↓, 2,   TOP2↓, 1,   TOP2↑, 1,   TOPflash↓, 1,   TumCG↓, 38,   TumCG∅, 1,   Wnt↓, 10,   Wnt/(β-catenin)↓, 4,   ZFX↓, 1,  

Migration ⓘ

annexin II↓, 1,   AntiAg↑, 2,   AP-1↓, 6,   AP-1↝, 1,   Ca+2↑, 12,   CAFs/TAFs↓, 1,   CAFs/TAFs↝, 1,   cal2↑, 1,   CDK4/6↓, 1,   CLDN1↓, 1,   CXCL12↓, 2,   E-cadherin↓, 4,   E-cadherin↑, 38,   F-actin↓, 2,   FAK↓, 9,   FAK↑, 1,   p‑FAK↓, 1,   Fibronectin↓, 3,   FTO↓, 1,   GLI2↓, 1,   ITGB1↓, 2,   ITGB4↓, 2,   ITGB6↓, 1,   Ki-67↓, 13,   MALAT1↓, 2,   MET↓, 1,   miR-130a↓, 2,   miR-139-5p↑, 1,   miR-200b↑, 1,   miR-206↑, 1,   miR-29b↑, 1,   miR-301a-3p↓, 1,   MMP1↓, 3,   MMP13↓, 4,   MMP17↓, 1,   MMP2?, 1,   MMP2↓, 49,   MMP2↝, 1,   MMP3↓, 3,   MMP7↓, 7,   MMP9?, 1,   MMP9↓, 60,   MMP9↝, 1,   MMPs↓, 16,   MUC4↓, 1,   N-cadherin?, 1,   N-cadherin↓, 26,   NEDD9↓, 2,   PDGF↓, 4,   PKA↓, 1,   PKCδ↓, 3,   RECK↑, 1,   RHBDD1↓, 1,   Rho↓, 5,   ROCK1↓, 5,   Slug↓, 15,   Smad1↓, 1,   SMAD2↓, 3,   p‑SMAD2↓, 8,   SMAD3↓, 6,   p‑SMAD3↓, 6,   SMAD4↓, 1,   Snail↓, 24,   Snail↑, 1,   SOX4↓, 1,   SOX4↑, 1,   T-cadherin↑, 1,   talin↓, 1,   TET1↓, 1,   TET1↑, 3,   TGF-β↓, 14,   TGF-β↑, 2,   TGF-β1↓, 2,   TIMP1↓, 1,   TIMP1↑, 4,   TIMP2↓, 1,   TIMP2↑, 3,   TIMP3↑, 1,   TumCA↓, 4,   TumCA↑, 1,   TumCI?, 1,   TumCI↓, 236,   TumCI↑, 3,   TumCMig↓, 159,   TumCMig↑, 2,   TumCP↓, 97,   TumCP↑, 1,   TumMeta↓, 41,   TumMeta↑, 2,   Twist↓, 11,   Twist↑, 1,   TXNIP↑, 1,   uPA↓, 8,   Vim?, 1,   Vim↓, 33,   vinculin↓, 1,   Zeb1↓, 11,   Zeb1↑, 1,   ZEB2↓, 1,   ZEB2↑, 1,   ZO-1↓, 1,   ZO-1↑, 4,   α-SMA↓, 3,   α-SMA↑, 1,   α-tubulin↑, 2,   β-catenin/ZEB1↓, 24,   β-catenin/ZEB1↑, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 37,   angioG↑, 1,   ATF4↑, 3,   ATF4↝, 1,   EGFR↓, 20,   p‑EGFR↓, 1,   EGR4↓, 1,   eNOS↓, 1,   EPR↑, 1,   HIF-1↓, 1,   Hif1a↓, 31,   Hif1a↑, 1,   Hif1a↝, 1,   NO↓, 1,   p‑PDGFR-BB↓, 1,   PHDs↑, 1,   TAMS↝, 1,   VEGF↓, 33,   VEGFR2↓, 5,  

Barriers & Transport ⓘ

AQPs↓, 1,   BBB↑, 2,   GLUT1↓, 9,   GLUT1∅, 1,   GLUT3↓, 1,   GLUT3∅, 1,   P-gp↓, 4,  

Immune & Inflammatory Signaling ⓘ

ASC↓, 1,   ASC↑, 1,   CD4+↓, 1,   COX2↓, 19,   COX2↑, 1,   COX2↝, 1,   CRP↓, 1,   CXCR4↓, 6,   ICAM-1↓, 2,   Igs↑, 1,   IKKα↓, 6,   p‑IKKα↓, 1,   IL1↓, 2,   IL1α↓, 2,   IL1β↓, 5,   IL6↓, 11,   IL6↑, 1,   IL8↓, 2,   Imm↑, 1,   Inflam↓, 11,   IRAK4↓, 1,   IκB↑, 1,   p‑IκB↑, 1,   JAK↓, 2,   p‑JAK↓, 1,   JAK1↓, 2,   JAK2↓, 5,   p‑JAK2↓, 2,   p‑JAK3↓, 1,   LIF↑, 1,   MCP1↓, 4,   MIP2↓, 1,   NF-kB↓, 50,   NF-kB↑, 4,   p‑NF-kB↓, 2,   p65↓, 4,   PD-1↓, 3,   PD-L1↓, 3,   PD-L1↑, 2,   PGE2↓, 6,   PSA↓, 1,   Th1 response↑, 1,   TLR2↓, 1,   TLR4↓, 3,   TNF-α↓, 8,   TNF-α↑, 2,  

Synaptic & Neurotransmission ⓘ

5HT↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 2,   NLRP3↑, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 6,   CDK6↓, 5,   CDK6↑, 1,   CDK6∅, 1,   RANKL↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 9,   BioAv↑, 9,   BioAv↝, 5,   BioEnh?, 1,   BioEnh↑, 1,   ChemoSen↓, 1,   ChemoSen↑, 39,   CYP1A2↑, 1,   CYP2A3/CYP2A6↓, 1,   Dose↓, 2,   Dose↑, 2,   Dose↝, 10,   Dose∅, 4,   eff↓, 12,   eff↑, 52,   eff↝, 1,   eff∅, 1,   Half-Life↓, 3,   Half-Life↑, 1,   Half-Life↝, 6,   MDR1↓, 1,   MRP1↓, 1,   P450↓, 1,   RadioS↑, 12,   selectivity↑, 28,  

Clinical Biomarkers ⓘ

AR↓, 6,   ascitic↓, 1,   BMD↑, 2,   BMPs↑, 1,   BP↓, 1,   CRP↓, 1,   EGFR↓, 20,   p‑EGFR↓, 1,   Ferritin↓, 1,   FOXM1↓, 1,   GutMicro↑, 1,   HER2/EBBR2↓, 6,   p‑HER2/EBBR2↓, 1,   IL6↓, 11,   IL6↑, 1,   Ki-67↓, 13,   LDH↓, 5,   LDH↑, 1,   Myc↓, 1,   Myc↑, 1,   NOS2↓, 1,   PD-L1↓, 3,   PD-L1↑, 2,   PSA↓, 1,   TP53↑, 1,  

Functional Outcomes ⓘ

AntiCan↓, 1,   AntiCan↑, 9,   AntiTum↓, 1,   AntiTum↑, 6,   cardioP↑, 2,   chemoP↑, 7,   ChemoSideEff↓, 3,   neuroP↑, 1,   OS↑, 6,   radioP↑, 2,   RenoP↑, 1,   Risk↓, 3,   Strength↑, 1,   Symptoms↓, 1,   toxicity?, 1,   toxicity↓, 3,   toxicity∅, 1,   TumVol↓, 7,   TumW↓, 5,   Weight∅, 1,  

Infection & Microbiome ⓘ

CD8+↑, 1,   Sepsis↓, 2,  
Total Targets: 669

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

chemoPv↑, 1,  

Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 13,   Catalase↑, 4,   GPx↑, 3,   GPx1↑, 1,   GSH↑, 5,   GSTs↑, 1,   H2O2↓, 1,   HO-1↑, 2,   Keap1↓, 1,   lipid-P↓, 4,   MDA↓, 1,   NRF2↑, 5,   ROS↓, 14,   ROS↑, 1,   SOD↑, 2,   SOD1↑, 1,   SOD2↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↑, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   cMyc↓, 1,   GlucoseCon↑, 1,   LDH↓, 1,   NADPH↓, 1,   NADPH↑, 1,   PPARγ↓, 1,  

Cell Death ⓘ

BAX↓, 1,   Casp3↓, 2,   iNOS↓, 2,   iNOS↑, 1,   JNK↑, 2,   MAPK↓, 2,   MAPK↑, 2,  

Transcription & Epigenetics ⓘ

Ach↑, 1,   other↓, 2,   other↝, 2,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↑, 1,  

Migration ⓘ

AntiAg↑, 1,   Ca+2↝, 1,   MMP9↓, 1,   PKCδ↓, 1,   p‑Rac1↓, 1,   TGF-β↓, 1,   TumCI↓, 1,   TumCI∅, 1,   TumCMig∅, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   VEGF↓, 1,  

Barriers & Transport ⓘ

BBB↑, 2,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 5,   CRP↓, 1,   IKKα↑, 1,   IL1↓, 1,   IL10↓, 1,   IL10↑, 1,   IL12↓, 2,   IL1β↓, 3,   IL6↓, 4,   Imm↑, 1,   Inflam↓, 13,   Inflam↑, 1,   MyD88↓, 1,   NF-kB↓, 4,   PGE2↓, 2,   TLR2↓, 2,   TLR4↓, 2,   TNF-α↓, 3,   TRIF↓, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 2,   ChAT↑, 1,  

Protein Aggregation ⓘ

Aβ↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 5,   BioAv↑, 6,   BioAv↝, 3,   Dose↝, 3,   Half-Life↓, 2,   Half-Life↝, 1,   Half-Life∅, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   ALP↓, 1,   AST↓, 1,   CRP↓, 1,   GutMicro↑, 1,   IL6↓, 4,   LDH↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 7,   cognitive↑, 2,   hepatoP↑, 7,   memory↑, 3,   neuroP↑, 12,   Pain↓, 1,   radioP↑, 1,   RenoP↑, 2,   Risk↓, 1,   toxicity↓, 14,   toxicity↝, 1,   toxicity∅, 7,  

Infection & Microbiome ⓘ

Bacteria↓, 1,   IRF3↓, 1,  
Total Targets: 104

Scientific Paper Hit Count for: TumCI, Tumor Cell invasion
12 Shikonin
11 Resveratrol
10 Berberine
10 Curcumin
10 Honokiol
9 Sulforaphane (mainly Broccoli)
9 Thymoquinone
7 Apigenin (mainly Parsley)
7 EGCG (Epigallocatechin Gallate)
6 Betulinic acid
6 Fisetin
6 Garcinol
6 Quercetin
6 Magnetic Fields
6 Piperlongumine
5 Ashwagandha(Withaferin A)
5 Lycopene
5 Magnolol
5 Metformin
5 Pterostilbene
4 Artemisinin
4 Chrysin
4 Phenethyl isothiocyanate
4 Rosmarinic acid
4 Silymarin (Milk Thistle) silibinin
4 Urolithin
3 Alpha-Lipoic-Acid
3 Propolis -bee glue
3 Gemcitabine (Gemzar)
3 Whole Body Vibration
2 alpha Linolenic acid
2 Astragalus
2 Astaxanthin
2 Baicalein
2 Boswellia (frankincense)
2 Selenium
2 Disulfiram
2 Copper and Cu NanoParticlex
2 Ellagic acid
2 Emodin
2 Ginkgo biloba
2 Grapeseed extract
2 Graviola
2 HydroxyTyrosol
2 Juglone
2 Magnetic Field Rotating
2 Nimbolide
2 Piperine
2 Cisplatin
2 Silver-NanoParticles
2 Vitamin C (Ascorbic Acid)
2 Zinc
1 Andrographis
1 Butyrate
1 Boron
1 Capsaicin
1 Celecoxib
1 Chlorogenic acid
1 chitosan
1 Cinnamon
1 Evodiamine
1 Ferulic acid
1 Gambogic Acid
1 Paclitaxel
1 Proanthocyanidins
1 Genistein (soy isoflavone)
1 γ-linolenic acid (Borage Oil)
1 Hydrogen Gas
1 Hydroxycinnamic-acid
1 Luteolin
1 5-fluorouracil
1 doxorubicin
1 immunotherapy
1 Noscapine
1 Oroxylin A
1 Oleuropein
1 Orlistat
1 Psoralidin
1 Germacranolide
1 salinomycin
1 Radiotherapy/Radiation
1 Salvia miltiorrhiza
1 Ursolic acid
1 Arsenic trioxide
1 Vitamin K2
1 VitK3,menadione
1 β‐Elemene
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:324  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page